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CD137 is a costimulatory molecule expressed on activated T cells. The 
signaling of CD137 into T cells upon ligation by its ligand, CD137L expressed on 
antigen presenting cells (APC), can potently enhance the activation of T cells. 
Reversibly CD137 can also induce signalling into APC via CD137L to promote 
activation and proliferation. By investigating the role of CD137L on myelopoiesis 
under inflammatory condition in vitro and in vivo, it was shown that CD137L reverse 
signaling represents a novel and potent growth and differentiating factor for murine 
myeloid cells during acute and chronic inflammation. In acute peritonitis and chronic 
aging model CD137L reverse signaling promotes myeloid cell proliferation and 
accumulation. Further investigations revealed the driving force behind the observed 
myelopoiesis as CD137+CD4+ T cells and absence of CD137L reverse signaling 
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Chapter 1 Introduction 
1.1 Hematopoiesis 
Hematopoiesis is the process of generating blood cells from hematopoietic 
stem cells (HSCs). The rapid turnover of blood cells such as erythrocytes and 
neutrophils requires a steady supply from the bone marrow, the primary 
hematopoietic organ in adult mammals. A small pool of undifferentiated, self-
renewing hematopoietic stem cells are responsible of giving rise to all the downstream 
blood cells. Classical viewing of hematopoiesis is usually composed of a cascade of 
differentiation, starting from HSCs at the top of the pyramid and ending with terminal 
differentiated cells that enter peripheral tissues. Except for T cells, B cells and certain 
tissue specific macrophages, the relationship of the differentiation state and self-
renewing ability is reciprocal, meaning that as the more differentiated the cells are, 
the lesser proliferative they are.   
 
Moreover, only the rare population of HSCs retains the ability of 
differentiating to all lineages of blood cells. The potential of committing to other 
lineages diminishes as the cells progress through several stages of intermittent 
phenotypes. For example, once the HSCs are committed to the fate of common 
myeloid progenitor cells (CMP), they have lost the potential of lymphopoiesis. When 
the stem cells have to make a decision of which lineage to commit to, they must 
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choose between the destiny of lymphoid lineage or myeloid lineage depending of the 
signals received from the external environment.  
 
Figure 1.1 Overview of hematopoieis . Differentiation of blood cells start with long 
term HSCs and move down the cascade of a series of intermittent progenitor cell 
types. HSC: hematopoietic stem cells. CLP: common lymphoid progenitor cells. CMP: 
common myeloid progenitor cells. MDP: macrophage-dendritic cell progenitor cells. 
CDP: common dendritic cell progenitor cells. CMoP: common monocytes-
macrophage progenitor cells. NK cells: natural killer cells.   
 
1.2 Myelopoiesis during steady state 
           Myeloid cells consist of a variety of cells from both innate and adaptive 
immunity, including neutrophils, macrophages, monocytes, myeloid dendritic cells 
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(DCs) and the less concerned eosinophils, mast cells and basophils (Fogg et al. 2006, 
Geissmann et al. 2010). Understanding the underlying mechanism of myelopoiesis 
during steady and disease state can significantly contribute to elucidation of  the 
potential pathogenic or regulatory role of each cell population.  
 
1.2.1 DC 
     First identified in mouse spleen by Ralph Steinman in 1973 (Steinman 2007), DCs 
are probably the most studied myeloid cells due to its central role of antigen 
presentation. Early studies on monocytes biology suggest that monocytes are the 
precursor of DCs when they migrate towards lymphoid tissue to present antigen to T 
cells (Randolph, Beaulieu et al. 1998). However, many of these studies were 
performed under the situation of inflammation and the origin of DCs during steady 
state were not well identified. Adoptive transfer and in vivo labeling reveal that while 
monocytes, macrophages and DCs may share a group of common myeloid progenitor 
cells in the bone marrow term macrophage-DC progenitor (MDP), DCs precursors 
become separated from the other two cell populations at the level of pre-DCs (Fogg  
et al. 2006, Liu and Nussenzweig 2010). They have the plasticity of differentiating to 
most of DCs found in lymphoid organ but not monocytes. Therefore, instead of being 
the offspring of monocytes, DCs has its own precursor termed common DCs 
progenitor cells (CDP). However, not all the DCs are of HSCs origin. Langerhans 
cells, the skin-residing DCs, are proven to arise from yolk sac (YS) myeloid 
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progenitor cells and fetal liver monocytes early in the embryonic development. The 
cells retain self-renewal ability and do not require a contribution of blood monocytes 
for replenishment at steady state (Hoeffel, Wang et al. 2012).  
 
1.2.2 Macrophage 
Aside from DCs, studies also show that local macrophages population such 
as microglia are resistant to radiation, indicating that some of the macrophages 
populations are able to self renew and be independent of HSCs origin . Geissman 
suggested that at least a few groups of myeloid macrophages, including microglia, 
may arise from YS origin instead of monocytes at homeostatic state (Geissmann, et al 
2010; Schulz, et al 2012). Indeed, studies show that myeloid progenitor cells from YS 
arrive at the embryo and seed in the brain and skin, which gave rise to microglia. The 
local microglia population is self-sustained throughout life without a contribution 
from blood monocytes. When the blood-brain-barrier is not disrupted, local microglia 
population is able to expand on its own (Ajami, Bennett et al. 2007). Moreover, a 
group of macrophages expressing a high level of F4/80, the classical macrophage 
marker, is found to originate independently from hematopoietic stem cells, suggesting 
two routes of myelopoiesis (Schulz, et al 2012, Gomez Perdiguero, et al. 2013, 




Similary to microglia, Kuffper cells, peritoneal macrophages and splenic 
macrophages were once thought to arise from blood monocytes after they extravasate 
from circulation. However, studies showed that this scenario holds true only in the 
condition of inflammation or when the local macrophage population is depleted. The 
only macrophage population that is steadily replenished by blood monocytes is the 
macrophages in lamina propria where there is a constant low degree of inflammation 
(Yona, et al 2012). In conclusion, blood monocytes are dispensable for tissue DC and 
macrophage population during steady state and they only transiently differentiate to 
DC and macrophage when inflammation occurs.  
 
1.2.3 Monocytes 
           As discussed above, monocytes were once considered the direct precursors of 
both DCs and macrophages and replenished both populations after they extravasate 
from the circulation. However, the identification of common DC progenitor cells 
(CDP) in the bone marrow suggested that monocytes may have distinct progenitors 
from DCs during steady state. Indeed although in the bone marrow the monocytes and 
DC can be derive from monocytes-DC progenitor cells (MDP, the differentiation 
program diverge at this stage (Hettinger, et al 2013).  Downstream of MDP are two 
distinct populations of progenitor cells: CDP and common monocytes progenitor cells 
(CMoP). CMoP express Ly6C and exclusively give rise to Ly6C+ blood monocytes 
but not DCs.  
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The revolutionary findings of DC and macrophages help to elucidate the 
lineages of different myeloid cells. However new questions arise, if monocytes do not 
differentiate to DCs and macrophages after they extravasate, what type of cells will 
they commit to?  
 
        Contradictory to previous dogma where the default differentiation program of 
monocytes is to become either DC or macrophage, Jakubzick reported that the degree 
of differentiation of monocytes after they infiltrate non-inflammatory tissue is 
minimal and the gene expression profile remain largely similar to blood monocytes 
but not to tissue macrophage and DCs, both of which are capable of self-renewal. 
Furthermore, the extravasated blood monocytes exit the tissue and migrate to lymph 
node and cross present antigen, a function exhibited by DCs (Jakubzick, et al 2013). 
The study revises the picture where monocytes were obliged to differentiate to 
macrophages or DCs after diapedesis and identify them as a unique mononuclear 
phagocyte population distinct from tissue macrophages and DCs.  
 
1.3 Altered myelopoiesis during inflammation 
Under normal circumstance the output of myeloid cell is kept at a steady rate 
to replace the constant loss of cells in the periphery. However, the rate of proliferation 
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as well as the nature of the downstream myeloid cells can be considerably altered by 
various disease states.  
 
1.3.1 Proliferation 
Pathogen invasion functions as an alarming signal to the immune system. In 
time supply of large number of phagocytes is necessary to keep the pathogen invasion 
in check before the adaptive immune response can take action. As the hematopoietic 
system is the major factory of immune cells, deficiencies in hematopoiesis can 
become the cause of deleterious diseases. For example, patients with neutropenia have 
low number of neutrophils and hence they suffer from recurrent infections (Lieschke 
et al. 1994, Ancliff et al. 2003, Catenacci and Schiller 2005, Cheung et al. 2007, 
Panopoulos and Watowich 2008, Bugl  et al. 2012). Under certain circumstances 
hematopoietic system can be manipulated by tumors to produce high number of 
immunosuppressive myeloid cells termed myeloid derived suppressor cells (MDSC) 
that infiltrate tumors and facilitate metastasis by suppressing T cell proliferation and 
function (Gabrilovich and Nagaraj 2009, Van Ginderachter, Beschin et al. 2010).  
 
Due to the self-renewing ability of HSCs; it is not surprising that the 
hematopoietic system is also prone to malignant disease where intrinsic mutation 
occurs and progenitor cells undergo uncontrolled growth. Numerous leukemic 
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diseases have been related to dysregulated hematopoiesis. Take acute myeloid 
leukemia (AML) as an example. Instead of continuing the journey towards mature 
myeloid cells, the committed progenitor cells fail to exit as mature cells and become 
arrested in an undifferentiated stage. As the degree of differentiation is reciprocal to 
the capability to proliferate these undifferentiated myeloid progenitor cells are prone 




Not only the proliferation rate but also the phenotype of the myeloid cells 
commit to can be influenced by the different disease states and in turn the 
differentiated myeloid cells can substantially shape the progress of the disease.  
 
In the periphery, although monocytes do not contribute to the homeostasis of 
DCs and majority of the tissue macrophages during steady state, they remain the bona 
fide population that quickly replenish phagocytes lost in the periphery during 
infection and infiltrate inflammatory tissue (Geissmann, et al. 2003, Serbina, et al. 
2003, Leon, et al. 2007, Bosschaerts  et al. 2010). During bacterial infection of 
L.monocytogenesis, monocytes from the blood are recruited to the spleen and 
differentiate to DCs. The production of Nitrite Oxide (NO) of these monocytes-
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derived DCs is essential for pathogen clearance and mice with reduced number of 
monocytes are more susceptible to infection-induced death. The ability of 
phagocytosis and production of microbiocidal peptides and NO deem them as one of 
the essential defense mechanism of innate immunity (Serbina  et al. 2003, Bosschaerts 
et al. 2010, Chong et al. 2011).  Similarly, viral infection induces rapid differentiation 
of blood monocytes to antigen-presenting DC within 18 hours ex vivo. (Hou, et al 
2012). The transition from monocytes to the highly effective antigen presenting DCs 
during infections makes them an ideal targeting population for ex vivo DCs 
generation. Therefore, understanding the biology of monocytes during infection can 
contribute considerably to the future development of immunotherapy. 
 
Under certain circumstances, however, the infiltration and differentiation of 
monocytes can become detrimental to the health of the animals. Numerous 
inflammatory diseases are known to recruit and drive the differentiation of 
inflammatory leukocytes at the site of inflammation. Taking colitis as an example, the 
disease progress is linked to uncontrolled proliferation of inflammatory neutrophils 
and macrophages in the bone marrow and spleen due to a skewing towards 
myelopoiesis by the hematopoietic progenitor cells in the inflammatory environment 
(Griseri et al. 2012, Oduro  et al. 2012). Moreover, it is reported that the 
differentiation program of monocytes is frequently switched from anti-inflammatory 
macrophage to inflammatory DCs by local environment (Rivollier, He et al. 2012).  
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During development of experimental autoimmune encephalomyelitis (EAE), 
inflammatory monocytes from peripheral blood also migrate to central nervous 
system (CNS) and give rise to myeloid DCs and microglia, which are responsible for 
presenting antigen to pathogenic CD4+ 
 
T cells and demyelination (Mildner et al. 2007, 
King  et al. 2009). In another instance, monocytes are recruited to site of plague and 
differentiate to macrophages and DCs, contributing to the formation of atherosclerotic 
lesion (Tacke, Alvarez et al. 2007).  
Therefore, studying the biology of monocytes differentiation during 
inflammation and identify the terminal phenotype that the cells have committed to 
enables development of novel therapeutic tool to block the actions of pathogenic DCs 
and macrophages.  
 
1.4 Factors that influence myelopoiesis during inflammation    
       During infection, granulocytes and monocytes exit the circulation and infiltrate 
tissues to eliminate invading pathogen, causing a rapid drop in the number of 
granulocytes and monocytes in the peripheral blood. Unlike lymphocytes which can 
be further expanded, granulocytes are postmitotic and do not undergo further 
proliferation. Peripheral monocytes can undergo proliferation and replenish the local 
population but the rate of expansion is still low compare to lymphocytes. To prevent 
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spread of the pathogen, bone marrow must quickly expand the myeloid population 
which is termed emergency myelopoiesis (Boiko and Borghesi 2012). When receiving 
signal of pathogen invasion, on one hand, bone marrow mobilizes T cells and B cells 
into the circulation to free up the limited space for expansion of the myeloid 
population, on the other hand the progenitor cells population experiences a shift from 
lymphopoiesis to myelopoiesis (Chandra, Villanueva et al. 2008, Oduro, Liu et al. 
2012)  
 
        Not all pathogens are disseminated to the bone marrow. How can a pathogen 
invading peripheral tissue deliver a message to the distant primary hematopoietic 
tissue and influence the output of myeloid cells? One possibility is through a cytokine 
level change in the serum. When granulocytes and macrophages fail to control local 
infection, pathogens spread and induce a systemic infection, causing a systemic 
reaction and release of proinflammatory cytokines from immune cells as well as 
epithelial cells (King and Goodell 2011). A number of cytokines have been reported 
to differentiate progenitor cells to myeloid cells. GM-CSF, M-CSF, IL-3 and G-CSF 
are the first few cytokines that are noted to support myeloid cells differentiation. Later, 
more cytokines, particularly those that are highly induced during inflammation, are 
reported to promote myelopoiesis. One example is IFN-gamma. Produced by Th1 T 
cells in large quantities, IFN-gamma is critical for clearance of intracellular bacteria, 
parasites and virus by inducing production of ROS in macrophages. Although in vitro 
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IFN-gamma has been found to limit the colony forming ability of human HSCs, 
during infection by intracellular bacteria, IFN-gamma was found to induce 
monopoiesis in the bone marrow in the case of E. muris, and L.monocytogenesis. 
Similarly, another member of the IFN family, IFN-beta, is also reported to induce 
myelopoiesis during acute inflammation (Diamond et al. 2011, MacNamara  et al. 
2011, Wilkison et al. 2012, Buechler  et al. 2013). Besides proinflammatory cytokines, 
component of bacteria and virus are also shown to induce myelopoiesis in the bone 
marrow. Toll-like receptors have been shown to be expressed on HSCs, and binding 
of LPS to TLR-4 on HSC can activate HSC and skew hematopoiesis towards 
myelopoiesis during acute and chronic exposure (Boettcher, et al 2012).  
 
Aside from acting on progenitor cells to promote differentiation to 
downstream granulocytes and monocytes, some proinflammatory cytokines and TLR 
ligands can shape the phenotype of cells. For instance, IFN-gamma is a maturation 
factor of classical inflammatory macrophages which is beneficial for pathogen 
clearance while the IL-4- induced alternative activated regulatory macrophages can 
suppress ongoing inflammation (Classen, et al. 2009). It is also reported that upon 
exposure to the milieu created by CD8+ T cells and DCs interaction that contains high 
level of IFN-gamma, IL-1, IL-6, IL-12p70p40 and TNF-alpha, monocytes 
differentiate to Tip DCs (Chong, et al. 2011). TLR signaling can also trigger rapid 
differentiation of monocytes to DCs and macrophages and the phenotype of cells that 
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monocytes commit to can significant shape the outcome of the disease (Krutzik, et al 
2005).Therefore, the phenotypes of the infiltrating myeloid cells strongly depend on 
the environmental cues that they encounter and identifying the factors involved in 
these processes allows efficient monitoring of myeloid cell differentiation at the site 
of infection.  
 
1.5 Biological function of CD137 
           One of the proinflammatory molecules that have received much attention in the 
last decade is the inducible T cell coactivator CD137 (TNFRSF9, 4-1BB), a member 
of the TNF receptor super family (TNFRSF). When first discovered, it was found on 
activated T cells (Kwon and Weissman 1989, Pollok  et al. 1993, Schwarz  et al. 
1993). As a very potent coactivator of T cells, CD137 enhances T cell proliferation, 
protects T cells from superantigen-induced cell death and reinforces proinflammatory 
cytokine production (Schwarz  et al. 1995). The primary role of CD137 activation in 
T cells leads to activation of CD8+ T cells which is the major force to eradicate 
intracellular bacteria and viruses (Shuford et al. 1997, Lee et al. 2002). Anti-CD137 
antibody is found to be able to reject established carcinoma, mastoma, and melanoma 
in animal models (Melero et al. 1997, Ju, Lee et al. 2005). The effect is so prominent 
that an agonistic anti-CD137 antibody has been developed for cancer therapy. 
Currently the antibody-based therapy in melanoma has already completed phase II 
clinical trials. (NIH reference number: NCT00612664)  
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Interestingly, activation of CD137 on T cells surprisingly suppresses the 
progression of a number of autoimmune diseases. Administration of agonistic CD137 
antibodies shows preference on IFN-gamma producing CD8+ T cell expansion but 
suppress CD4+ T cells activation. In autoimmune disease models including collagen 
Type II arthritis and EAE, expansion of this CD8+
 
 T cell population surprisingly 
ameliorates the disease progression (Foell et al. 2004, Seo, Choi et al. 2004, Kim, 
Choi et al. 2011). IFN-gamma dependent expansion of IDO-mediated immune 
suppression is the prime mechanism while CD137-mediated suppression of 
pathogenic Th17 T cells also partly contributes to the disease suppression. 
As more and more attention was drawn towards CD137, studies continued to 
report expression of CD137 on a wide range of immune cells including monocytes, B 
cells, NK cells and DCs. With a few exceptions the activities of the molecule on the 
cells are mainly activating. In DCs, CD137 provides a survival signal as well as 
activation signal to enhance costimulatory molecule and cytokine production 
(Futagawa et al. 2002, Choi et al. 2009). In non-immune cells CD137 is found on 
epithelial cells and endothelial cells and ligation of the molecule reinforces cytokine 
and chemokine production that enhance leukocyte infiltration (Quek et al. 2010, 





1.6 CD137/CD137L bi-directional signaling system 
A central feature of TNFRSF is that both receptor and ligand can transduce 
signaling into the cells they are expressed on, respectively (Domonkos et al. 2001). 
Not only can CD137 transduce a signal into T cells upon crosslinking, its ligand, 
CD137L, can also signal into cells on which it is expressed. Expression of CD137L is 
mainly found on antigen presenting cells (APCs) including DCs, macrophages and B 
cells (Bossen et al. 2006, Yang et al. 2008). The signaling through CD137L is termed 
reverse signaling to distinguish it from the signaling through CD137. Expression of 
CD137L is, however, not found exclusively on APC. In the past decade, the molecule 
has been also reported to be present on T cells, endothelial cells, microglia and 
hematopoietic progenitor cells (Jiang 2008, Jiang et al. 2008).  
 
Figure 1.2 Illustration of bidirectional signaling of CD137 and CD137L on APC 







1.7 Reverse signaling of CD137L on APC 
1.7.1 Importance of understanding DC biology 
APCs are a group of immune cells that can present specific antigen to T cells 
and hence bridge the innate and adaptive immunity. The adaptive immunity against a 
certain pathogen largely depends on how efficient the antigen is presented. DCs are 
probably the best known APC since 1973 reported by Steinman (Steinman 2007).  
The high level of MHC-II and costimulatory molecules expressed on DCs makes 
them the most efficient APC. These properties of DCs are determinants of the 
following immune responses. DCs subsets have been categorized based on surface 
markers, function and tissue location in the human and murine system, and it was 
agreed that different DCs subsets have their own preference of T cell stimulation, and 
eventually determining the following immune responses. For example studies 
focusing on DCs ontogeny have identified a particular subset of CD103+ DCs 
responsible for tolerance in the gut. On the other hand the CD103-
 
 DCs is the 
pathogenic DCs subset that drives the Th17 response in intestinal inflammation 
(Matteoli et al. 2010, Rivollier et al. 2012). Therefore, by studying the different 
phenotypes and functions of DCs subset, it helps to identify therapeutic targets in 
disease models for manipulations.  
       Since the discovery of DCs and their powerful roles in antigen presentation, the 
cells have been of the central interest for immunotherapy. Researchers are keen to 
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develop antigen-specific DCs vaccines that can target tumor antigen. However, this 
approach requires ex vivo expansion of DCs. In man, GM-CSF plus IL-4 or Flt-3 
ligand have proven to be effective in differentiating monocytes from cord blood or 
peripheral blood mononuclear cells (PBMC) to DCs (Romani et al. 1994, Sallusto and 
Lanzavecchia 1994). In the murine system, bone marrow is a more readily available 
source as it contains relatively high number of hematopoietic progenitor cells and 
monocytes compared to peripheral blood. Immature DCs usually have low level of 
MHC-II and costimulatory molecule and hence a weak antigen presenting ability, 
properties that may induce T cell anergy and tolerance instead of activation (Sallusto 
et al. 1995, Van Gool et al. 1996). The reagents used for maturation can also influence 
the phenotype of DCs. Therefore, in order to derive fully functional DCs that can 
effectively deliver antigen to T cell, maturation is an essential step. LPS, IFN-gamma, 
IL-1 and TNF-alpha are some of the common reagents to induce DCs maturation. In 
spite of the potent maturation effect of these reagents, when it comes to clinical 
application, it is more desirable if fewer reagents are required for the culture while 
maintaining the same activation state to minimize complication.  
 
1.7.2 Reverse signaling of CD137L on human monocytes and immature DCs 
In the pioneering study on CD137L reverse signaling, Schwarz et al showed 
that human monocytes proliferate upon the treatment of recombinant CD137 protein, 
partly by inducing production of M-CSF in an autocrine and/or paracrine manner 
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(Langstein et al. 1998, Langstein et al. 1999). Later it was demonstrated that 
activation of CD137L on immature DCs derived from human cord blood monocytes 
enhances expression of costimulatory molecules and IL-12p70 production (Kim et al. 
2002, Lippert et al. 2008). The CD137L-matured DCs can also induce higher T cell 
proliferation than its control, suggesting that CD137L can function as a maturation 
agent in the process of DCs differentiation. Another study on CD137L reverse 
signaling on APC showed that when CD137L is expressed in DCs by a vector, 
costimulatory molecules such as CD80, CD86 and CD40 are also upregulated 
(Yurkovetsky et al. 2006). 
 
Taking a step further, Kwajah et al found that crosslinking of CD137L on 
human blood monocytes induces differentiation to a distinct type of DCs (Kwajah and 
Schwarz 2010). Although these CD137L-DCs have reduced HLA-DR and IL-12p70, 
both of which are essential for a Th1 response, they can nonetheless potently induce T 
cell proliferation in allogenic mixed lymphocyte reaction (MLR), proving their 
capability in antigen presentation and marking them as a potential tool for DCs 
therapy. The T cells primed by CD137L-DCs also have higher cytotoxic activity than 
classical DCs. Moreover, unlike classical DCs which need maturation by LPS, the 
property of CD137L-DCs is not further enhanced by LPS, indicating that CD137L 
alone can function as both a differentiating factor as well as maturation factor. These 
findings promise clinical potential particularly for DCs-based immunotherapy when a 
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large number of DCs expanded ex vivo is desirable. Compared to classical DCs which 
need three factors to become fully mature, CD137L-DCs require only one factor to 
derive a functional inflammatory DCs and hence can significantly reduce the cost and 
potential complications.  
 
1.7.3 Reverse signaling of CD137L on macrophages 
Macrophages are another important group of myeloid APC involved in both 
innate and adaptive immunity. Although the majority of the macrophages possess the 
basic function of phagocytosis , ROS production and release of cytokines, they are a 
highly heterogeneous group categorized based on the function and tissue they reside 
in. For example, while the major function of red pulp macrophages in the spleen is to 
engulf aged red blood cell, osteoclasts in the bone marrow perform bone resorption. 
Studies up to date have shown a functional role of CD137L reverse signaling on a 
wide range of macrophages, including microglia, peritoneal macrophages and 
osteoclasts (Shin et al. 2006, Shin et al. 2007, Jeon et al. 2010, Yeo et al. 2012). On 
bone marrow derived macrophages, CD137L reverse signaling prolongs survival of 
the macrophages and enhances cytokine production (Kim et al. 2009). The interaction 
of CD137 and CD137L is also essential for macrophages mobilization because in the 
peritoneal cavity influx of macrophages is impaired in CD137-/- mice due to a reduced 
level of IL-10 (Shin et al. 2007). Stimulation of CD137L in macrophages can be also 
involved in pathological conditions. For instance, activation of microglia in the brain 
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via CD137L can induce ROS production and proinflammatory cytokine release which 
lead to apoptosis of oligodendrogcytes. In brain section of mice with experimental 
autoimmune encephalomyelitis (EAE), expression of CD137L and activation of 
microglia were simultaneously increased (Yeo et al. 2012).  
 
Figure 1.3: Illustration of reverse signaling of CD137L on monocytes, DCs and 
macropahges. 
 
1.8 Effect of CD137 on hematopoietic stem cells 
In recent years, it was gradually recognized that the expression of CD137L 
reaches far beyond the territory of differentiated immune cells. The expression of 
21 
 
CD137L is found on a small subset of human cord blood CD34+ hematopoietic 
progenitor cells as well as on murine Lin- 
 
progenitor cells (Jiang 2008, Jiang et al. 
2008). Crosslinking of CD137L reverse signaling on the HSCs induces proliferation 
of the cells and enhances colony forming. The treated cells also undergo extensive 
morphological changes, a sign of activation and differentiation. Functional studies 
found that the cells exhibit characteristic of macrophages. On the more committed 
progenitor cells that have restricted potential in differentiation, CD137L reverse 
signaling selectively induces proliferation and differentiation of common myeloid 
progenitor (CMP) cells other than granulocytes-macrophages progenitor (GMP) cells 
(Jiang and Schwarz 2010). While CD137L supports bone marrow cell proliferation 
and differentiation just like other hematopoietic factors, it antagonizes the effect of G-
CSF in the fate decision of monocytic and granulocytic lineage by biasing 
differentiation towards the monocytic lineage.  
1.9 Biphasic role of CD137L reverse signaling 
Although the majority of the studies have focused on the activating properties 
of CD137L, it should be noted that CD137L can exhibit regulatory roles at different 






In vitro coculture of PBMC on culture plates coated with recombinant CD137 
protein showed that in early phase of monocytes activation, CD137L reverse signaling 
induces ROS that caused apoptosis of T cells (Kwajah, Mustafa et al. 2011). However, 
if monocytes are exposed to CD137 for a longer period, the cells become 
inflammatory DCs that stimulate T cell proliferation (Kwajah and Schwarz 2010).  
This biphasic role of CD137 represents a tightly regulated mechanism: when the 
exposure to CD137 is transient and at the early phase of infection, the signal functions 
as a regulatory signal to remove potential pathogenic T cells. It is also possible that 
depletion of excess T cells with low specificity by monocytes in the early phase of an 
immune response is to empty the repertoire for future expansion of antigen –specific 
T cells. If the exposure is prolonged, the signal becomes a persistent inflammatory 
response and indicates prolonged pathogen invasion. Therefore the reverse signal of 
CD137L on monocytes switches to an activating signal to induce DC differentiation 
and eventually an augmented immune response. 
 
1.9.2 B cells 
Not only does CD137L on monocytes exhibit a biphasic function, stimulation 
of CD137L on B cells also showed a similar phenomenon where in vitro stimulation 
of CD137L on B cells induces proliferation and costimulation (Pauly et al. 2002, 
Zhang  et al. 2010) but constitutive expression of CD137L on APC of transgenic mice 
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leads to B cell deletion as the mice age, suggesting that a persistent signal of CD137L 
is deleterious for B cells (Zhu, Flies et al. 2001). Additionally aged CD137L-/-
 
 mice 
have a higher tendency of developing B cell lymphoma and CD137L is found to 
regulate hyperproliferation of B cells in lymph nodes (Middendorp et al. 2009).  
Again the data suggested that CD137L reverse signaling can have significant distinct 
impacts on APC depending on the length of exposure time.   
1.10 Conflicting findings for CD137L reverse signaling  
          The biphasic role of CD137L reverse signaling suggests that the 
CD137/CD137L system is more complicated than expected. In spite of the progress in 
understanding the CD137/CD137L reverse signaling system, conflicting data exist 
among different research groups.  
 
1.10.1 Anti-tumor effect 
Taking the anti-tumor effect mediated by CD137 as an example. With the 
impressive potency to reject established tumor by agonistic anti-CD137 antibody, one 
may expect mice lacking the gene for CD137 have poorer immune protection from 
tumor development. Indeed in the first report by Kwon et al, CD137-/- mice showed 
higher mortality and larger tumor size when inoculated with melanoma cells (Ju, Lee 
et al. 2005). However, years later, the same groups utilizing a different set of tumor 
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cell lines, and reported completely opposite findings that WT mice are more 
susceptible to tumor growth than CD137-/- mice (Choi et al. 2010). The discrepancy 
between the two reports probably has its root in the different properties of the tumor 
cell lines that have differential sensitivity to CD8+ T cells and NK cells killing. In the 
latter study the authors find that IFN-gamma by CD8+
          
 T cells actually leads to 
depletion of periphery NK cells, rendering the mice more susceptible to tumor growth. 
The striking difference in response suggested that, depending on the type of tumor, 
the anti-tumor effect of CD137 may be detrimental instead of beneficial. 
1.10.2 Autoimmune disease 
          In autoimmune disease models, similar conflicts were also noted. While 
administration of agonistic anti-CD137 antibodies suppresses development of 
autoimmune disease (Kim et al. 2011), CD137L-/- mice are protected from EAE. The 
resistance of CD137L-/- mice is largely due to reduced VCAM-1 expression which in 
turn leads to lower number of leukocytes infiltration and demyelination of the spinal 
cord (Martinez Gomez et al. 2012). One possible explanation to resolve the conflict is 
that agonistic antibodies tend to overactivate T cells beyond the physiological 
situation and the large amount of IFN-gamma released by CD8+ T cells leads to IDO-
mediated immune suppression. Simultaneously the agonistic antibodies prevent the 
reverse signaling of CD137L which is required for leukocytes infiltration in the CNS 
for disease progression. In the case when CD137L-/- mice are employed, signaling 
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through both the ligand and the receptors are abolished. Even without the IFN-gamma 
from CD8+
 
 T cells, removing CD137L reverse signaling alone is sufficient to prevent 
the disease progression.  
1.10.3 Osteoclastogenesis 
Osteoclasts are macrophages derived from hematopoietic stem cells and 
mainly involved in bone resorption. Differentiation of osteoclasts largely depends on 
M-CSF and RANKL secreted by stromal cells. During inflammation bone 
abnormalities like periodontitis and osteomyelitis are frequently reported and 
complicate disease progress. Proinflammatory cytokines upregulated during infections 
including IFN-gamma and IL-12p70 are found to inhibit osteoclast differentiation 
(Wilkison, Gauss et al. 2012).  
 
The influence of CD137 on osteoclastogenesis was firstly reported by Saito 
and colleague that osteoblasts upregulate CD137 when infected with E.coli, BCG and 
streptococcus and suggested that the expression of CD137 may influence the lineage 
commitment of bone marrow macrophages (BMM) to osteoclasts since BMM express 
CD137L. Indeed in the presence of recombinant CD137 immobilized on culture plate 
number of mature osteoclasts were significant reduced compared to control culture.  
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The findings are further confirmed by two more studies from Choi and 
colleague that differentiation of BMM to osteoclast by M-CSF and RANKL are 
inhibited by crosslinking of CD137L (Shin et al. 2006, Shin et al. 2006). The two 
latter studies also elucidated that the underlying mechanism of CD137L-mediated 
inhibitions are dependent on increase level of Type I IFN-beta and IL-10 from WT 
mice because depletion of either cytokines partly rescued the differentiation of 
osteoclasts. The last study by Senthikumar and colleague also reported similar 
findings that CD137L reverse signaling inhibits osteoclastogenesis (Senthilkumar and 
Lee 2009). Importantly this study found that the inhibition depends on cell-cell 
interaction between CD137+ T cells and CD137L+ osteoclast progenitor cells, 
indicating potential involvement of CD137+
 
 T cells in myeloid cell differentiation.  
Interestingly conflicting data are reported regarding the CD137/CD137L 
reverse signaling on osteoclast. A study argued that expression of CD137 enhances 
osteoclasts differentiation due to cis expression of both receptor and ligand on the 
osteoclast precursors and both signaling through CD137 or CD137L can positively 
regulate osteoclast differentiation(Yang et al. 2008). The study present a very strong 
piece of evidence that WT mice have lower bone density than the CD137-/- mice, 
characteristic of more actively osteoclastogensis and bone resorption. Although the 
authors suggested that the potential discrepancy may lie in different strains of mice 
used (C57BL/6 vs Balb/c) as well as the length of culture time, the conflicts would be 
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better resolved in model using CD137L-/- 
 
mice or double knock out mice of CD137 
and CD137L where the involvement of CD137L can be completely excluded. 
Moreover the level of osteoclastogenesis in mice should be assessed during 
inflammation state because pathogen invasions are known to influence osteoclast 
differentiation. 
1.10.4 NK cells 
The majority of the studies on CD137 have been conducted in the murine 
system. However, it should be noted that a discrepancy exists between the human and 
murine system on the effects of CD137. The difference is best illustrated in NK cells. 
When CD137 is activated on murine NK cells, the signal is stimulatory and favors a 
better cytotoxicity for malignant cell clearance. However, researchers also found that 
in cocultures of human AML cell lines with human NK cells, the effect of CD137 is 
surprisingly inhibitory, suggesting that in the human system, activation of CD137 on 
NK cells is probably undesired for an anti-tumor effect (Baessler et al. 2010). Such 
species differences should be taken note off as they may significantly impact the 







More recently CD137L has also been found on HSCs and microglia (Jiang, 
2008 a b; Yeo, 2011; ). Signaling of CD137L into these cells induces proliferation, 
activation and differentiation. The wide range of cells that CD137L is expressed on 
and numerous functions suggest an essential role of the molecule in the immune 
system. Its expression on HSCs particularly triggered interest in whether CD137L 
reverse signaling may regulate hematopoiesis. 
 
When CD137-/- mice were first generated, it was found that in spite of the 
normal development naïve CD137-/- mice have nonetheless higher numbers of 
myeloid progenitor cells and colony forming units than WT mice. BrdU incorporation 
also indicates a higher turnover rate of the progenitor cells, suggesting that in the 
absence of CD137 myeloid progenitor cells are undergoing a more extensive process 
of proliferation (Kwon et al 2002). Later, Lee and colleague showed that while the 
absence of CD137 or CD137L has no effect on the number of long-term and short-
term stem cells, both CD137-/- and CD137L-/- mice have higher numbers of myeloid 
progenitor cells during steady state and progenitor cells from the two knock out 
strains have better reconstitution ability in irradiated mice than WT, particularly in the 
myeloid and B cell lineage, confirming the previous finding (Lee, Park et al. 2008). 
The researchers continued to identify which downstream myeloid populations are 
most affected and found that the number of DCs in the lung was decreased in WT 
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compared to CD137-/- and CD137L-/-
 
 mice. Hence, it was concluded that CD137 
limits myelopoiesis particularly DCs development during steady state.   
Contradictory, Jiang et al reported that in both the human and murine system 
crosslinking of CD137L by recombinant CD137 protein on hematopoietic stem cells 
induced morphological change and activation (Jiang 2008, Jiang, Yue et al. 2008). 
Proliferation assays further shows that the progenitor cells proliferate when 
crosslinked by CD137. Functional studies on the CD137-treated progenitor cells 
shows that the differentiated cells exhibit a phenotype that is highly similar to 
macrophages but not DCs evidenced by an enhanced phagocytic activity but reduced 
T cell stimulation in allogenic MLR. Furthermore, CD137L-treated human monocytes 
induce differentiation towards DCs that have strong T cell stimulation ability, clearly 
contrasting the report that CD137L limits DCs development in the lung during steady 
state (Kwajah and Schwarz 2010). In another study where Zhu and colleague 
selectively expressed CD137L in APC, the level of CD11b+
 
 cells were increased by 3-
fold (Zhu, Flies et al. 2001, Kuang, Weng et al. 2012). How can the seemingly 
conflicting data be resolved?  
It should be noted that there are fundamental differences in the experimental 
set up between the two groups’ work. While Lee and colleagues utilized naïve 
CD137-/- and CD137L-/- mice (Lee et al. 2008), Jiang and Kwajah investigated the 
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effect of CD137L in vitro where high level of CD137 recombinant protein was used 
(Jiang 2008, Jiang et al. 2008, Kwajah and Schwarz 2010). The latter experiment set 
up is closer to the scenario where CD137 protein is induced on T cells and endothelial 
cells by pathogen infection. To better resolve the conflict it is necessary to perform 
study in vivo with inflammation.  
 
1.11 The role of T cells in maintaining myelopoiesis 
The study by Senthikumar found that CD137+ T cells and CD137L+ 
osteoclast progenitors interact and mediates signaling through both directions, 
suggesting potential involvement of CD137+ 
 
T cells in lineage decision of progenitor 
cells. Studies in bone marrow transplants indicated that T cells are essential for 
successful bone marrow engraftment and reduced graft failure risk (Kaufman et al. 
1994). Since hematopoietic stem cells and monocytes express CD137L, can T cells be 
a source of CD137 in vivo?  
1.11.1 Presence of T cells in bone marrow 
Accumulations of T cells have been reported in human and murine bone 
marrows (Slifka et al. 1997, Price and Cerny 1999, Di Rosa and Pabst 2005, Herndler-
Brandstetter et al. 2011). The majority of the T cells are mainly effectors and memory 
T cells (Mazo et al. 2005). It is believed that the major role of these T cells in the 
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bone marrow is to combat malignant cells and infections that have been disseminated 
to the bone marrow (Slifka et al. 1997). The role of these T cells in hematopoiesis, 
however, remains poorly unknown.  
 
1.11.2 Primary myelopoiesis 
In the past few years it has become clear that T cells, though player in the 
adaptive immune system can influence the output of myeloid lineage cells in 
hematopoiesis. Monteiro et al shown that athymic mice have reduced matured 
myeloid cells and reconstitution of CD4+ T cell but not CD8+ T cell restore the normal 
myelopoieisis (Monteiro et al. 2005). While the colony forming units of granulocytes 
and macrophages are reduced, the normal myelopoiesis clearly depends on the growth 
factors released by T cells. The T cells taking part in this process are activated T cells 
that have reduced CD62L but increased levels of CD69, concluding that it was the 
antigen-experienced CD4+
 
 T cells in the bone marrow that are the key players of 
hematopoieisis.  
Apart from maintaining normal hematopoiesis T cells are also found to enter 
the bone marrow during infection of LCMV and transient production of IFN-gamma 
by these T cells is essential to enhance monopoiesis over granulopoiesis. In IFN-
gamma-/- mice, the number of monocytes is considerably reduced compared to WT 
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mice when infected with LCMV (de Bruin et al 2012). This preference of monocytes 
production instead of granulocytes production supports a greater influx of monocytes 
to peripheral tissue to eliminate intracellular pathogen.  
 
1.11.3 Extramedullary myelopoiesis 
Not only can T cells influence primary myelopoiesis but also secondary 
myelopoiesis in the spleen which is also termed extramedullary myelopoiesis. 
Effector T cells in the spleen are  demonstrated to promote extramedullary 
myelopoiesis through production of GM-CSF and IL-3. On the other hand, Foxp3+
 
 
regulatory T cells suppress the extramedullar myelopoiesis by suppressing the 
differentiation of naïve T cells to hematopoietic factor producing T cells, mainly 
through the production of TGF-beta (Lee et al. 2009).  
1.11.4 Mechanism of T cell mediated myelopoiesis 
Piecing together the evidence it is strongly suggested that activated T cells 
are a driving force of myelopoiesis to contain infections. Then what is the underlying 




One possible route is through soluble factor. Upon activation T cells produce 
IL-3, stem cell factor, GM-CSF and G-CSF all of which can support hematopoiesis, 
particularly myelopoiesis. Involvement of IFN-gamma and Type-I IFN in monocytes 
production further proves that T cells can modulate myelopoiesis (Deonarain et al. 
2003, MacNamara et al. 2011). 
 
 Apart from releasing cytokines such as GM-CSF and G-CSF which support 
proliferation and differentiation of myeloid cells, another possible mechanism of T 
cell mediated myelopoiesis is through interaction of surface molecule in close contact 
with progenitor cells. Since CD137 is expressed most abundantly on activated T cells 
while its ligand is found on hematopoietic stem cells and monocytes, it is postulated 
that T cells may promote myelopoiesis both through surface-bound CD137 and 
soluble cytokines. 
 
1.12 Immuneaging, inflammation and myelopoiesis 
Aging is a process accompanied by low grade chronic inflammation. In both 
man and mice remodeling of hematopoiesis occurs through a shift from 
lymphopoiesis to myelopoiesis. Accumulated numbers of myeloid cells are observed 
in aged adults with diminishing numbers of lymphocytes. Not only do the numbers of 
myeloid progenitor cells exceed lymphoid progenitor cells but also do hemtaoptoitic 
34 
 
stem cells tend to develop a bias towards myeloid lineage differentiation (Morrison et 
al. 1996). The enhanced myelopoiesis is also evidenced by an increased number of 
myeloid cells in the bone marrow. This phenomenon can be viewed as the aging of 
immune system because of the diminishing output of lymphocytes of adaptive 
immune system. 
 
Figure 1.4 Illustration of the changed balance between lymphopoiesis and 
myelopoiesis during aging. 
 
1.12.1 Mechanism and consequence of immuneaging 
Various mechanisms have been suggested to explain the imbalance of 
lymphopoiesis and myelopoiesis in aged humans and animals. DNA damage and 
shortened telomerase in hematopoietic stem cells have been reported to be related to a 
weaning potential of lymphoid differentiation (Lieber and Karanjawala 2004, Rossi, 
Bryder et al. 2007, Nalapareddy et al. 2008). Changes in the microenvironment of the 
bone marrow including reduced support from stromal cells and increased levels of 
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inflammatory cytokines have been reported to contribute to the dysregulated 
hematopoiesis. Persistent chronic inflammatory signals such as tumor and 
autoimmune disease that developed during aging are also potential driving forces of 
myelopoiesis because many of the proinflammatory cytokines including INF-gamma, 
Type-I IFN and IL-6 have been reported to modulate myelopoiesis during infection 
(Deonarain et al. 2003, MacNamara et al. 2011).  
 
The consequence of imbalanced hematopoiesis can have severe 
complications in elderly as the myeloid population is expanding at the expense of the 
lymphoid population which is the central player of adaptive immunity. With a shrunk 
repertoire of lymphoid progenitor cells, the adaptive immune system becomes less 
efficient to respond to vaccination and to eliminate malignant cells, which explains 
the reduced vaccination efficacy and higher tumor incidents in elderly (Goodwin et al. 
2006). With growing aging populations around the world, it would be of clinical 
importance to understand the disrupted hematopoiesis in elderly so that novel 
therapeutic tools can be developed to monitor the process.  
 
1.12.2 Intervention of immuneaging          
Recently researchers have managed to reboot the lymphopoiesis in mice, 
particularly the production of naïve B cells from bone marrow by removing 
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circulating B cells. It is hypothesized that circulating memory B cells exhaust the 
repertoire of the naïve B cell compartment and send a negative signal to 
hematopoietic stem cells for B cell lymphopoiesis. Therefore, by removing existing B 
cells the hematopoietic system may sense a need for producing more B cells.  
Experiments that deplete B cells using anti-CD19 antibodies showed that the output of 
naïve B cell in the bone marrow is restored when the aged mice have undergone more 
than one round of B cell depletion. Most importantly, the treated aged mice had an 
enhanced response to antigen stimulation (Keren, Naor et al. 2011).  
 
It is possible, however, to rejuvenate the hematopoiesis from another aspect 
by understanding the mechanism of skewed myelopoiesis, particularly at the level of 
the progenitor cells. By identifying the molecules that are driving the myeloid bias, it 
may be possible to rekindle the lymphopoiesis by blocking the myelopoiesis signaling 
pathway in HSCs by the responsible molecules. The proinflammatory property of 
CD137L reverse signaling makes it a potential influential factor of immuneaging. 
Detection of CD137L on HSCs also suggests that it may play a role in the lineage 
decision making. However, it remains unclear whether this influence is only transient 
during emergency like infection or is a sustained, accumulative force that acts on 





1.13 Aim and scope 
        Reports on CD137L reverse signaling suggest that CD137L may promote 
myeloid proliferation, activation and differentiation of APCs and HSCs. However, 
contrasting data from different groups indicate that CD137L reverse signaling may 
have different activities depending on the respective physiological conditions. Species 
difference may also exist between human and murine cells for their response to 
CD137L reverse signaling. This project aims at resolving several conflicts and adding 
knowledge of CD137L reverse signaling during acute and chronic inflammation.  
 
      The project aims at answering the following four questions: 
1. Can CD137L reverse signaling in murine monocytes induce DCs 
differentiation?  
2. Does CD137L reverse signaling promote myelopoiesis during acute 
inflammation like infection?  
3. What is the role of CD137L reverse signaling in myelopoiesis during 
chronic inflammation in the context of aging? 




       By answering these questions, it is hoped to evaluate the potential of testing 
CD137L-DCs in murine model and also to resolve the conflicts existing in the role of 
CD137L reverse signaling in myelopoiesis. Eventually this project is aimed at 
elucidating the underlying mechanism and cell populations responsible for the 
CD137L reverse signaling on myelopoiesis under various circumstances to provide 















Chapter 2 Materials and Methods 
2.1 Mice  
Female BALB/c and C57BL/6 mice between 8 and 16 weeks of age were 
used as a source of bone marrow cells and femur bones. Animals were specific 
pathogen free, and kept with free access to food and water in the animal care facility 
at the National University of Singapore under the institutional guidelines for usage of 
experimental animals. CD137-/- and CD137L-/-
 
 mice were generated as described 
previously (Kwon 2002). 
In the aging model gender and age matched mice of WT, CD137-/- and 
CD137L-/-
 
 origins were maintained until the age of 12 months. Mice with visible skin 
lesion or dermatitis due to fighting were excluded from the study. 3-months old mice 
were used as young controls. 
2.2 Infection of mice 
BALB/c mice were each infected intranasally with 106 colony forming units 
(CFU) of the wild type Bordetella pertussis BPSM strain in 20 μl as described 
previously. Mice were sacrificed 1, 3 and 7 days post-infection and femur bones were 
isolated for immunohistochemistry (IHC).  
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C57BL/6 mice (6 - 8 weeks old) were infected intranasally with 107
 
 
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) per mouse. After 3 weeks 
mice were euthanized and femur bones were collected for IHC. 
8 - 10 week old C57BL/6 WT and CD137-/- mice were intraperitoneally 
injected with 106
 
 CFU Escherichia coli. Mice were sacrificed 2 days later and bone 
marrow cells were isolated. 
8 - 10 week old C57BL/6 mice were infected intranasally with 5 PFU 
Influenza A virus (PR8, H1N1) per mouse. Uninfected naïve mice were used as 
control. Mice were sacrificed 4 days post-infection and femur bones were collected 
for IHC. 
 
 8 - 10 week old C57BL/6 mice were i.p. injected with 100 μl of 1 mg/ml 
LPS (Escherichia. coli 0111:B4, Sigma-Aldrich, St Louis, MO, USA). Naïve mice 






2.3 Preparation of bone marrow cells and splenocytes 
Mice were euthanized by CO2
 
 inhalation. The femur bones were dissected 
and the bone marrow was flushed out aseptically with phosphate-buffered saline 
(PBS), 2 mM EDTA using a 10 ml syringe and 27G needle. Total bone marrow cells 
were passed through a 30 µm filter (Miltenyi Biotec, Bergisch Gladbach, Germany), 
washed with PBS containing 2 mM EDTA and resuspended in RPMI1640 medium 
(Sigma-Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and 100 μg/ml streptomycin and 2.1 Mm L-glutamine.  
Spleens were aseptically removed from the abdominal cavity and minced 
through a 40 μm nylon cell strainer (Becton Dickinson, Franklin Lakes, New Jersey, 
USA) with a 5 ml syringe core in 10 ml of PBS. Red blood cells were depleted with 
Tris-NH4
 
Cl lysis buffer. Splenocytes were washed with PBS containing 2 mM EDTA 
and resuspended in RPMI1640 medium supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and 100 μg/ml streptomycin and 2.1 Mm L-glutamine.  
2.4 Isolation and culture of bone marrow monocytes 
           Murine monocytes were isolated from8-10 weeks old mouse bone marrow by 
negative enrichment using EasySep™ Mouse Monocytes Enrichment Kit (Stem Cell 
Technologies, Vancouver. Canada). In brief, bone marrow cells were labeled with a 
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cocktail of biotinylated antibodies against T cells, B cells, progenitor cells, 
erythrocytes and granulocytes in PBS with 5% normal rat serum at 4 °C for 15 
minutes. The labeled cells were washed by PBS with 5% normal rat serum and 
centrifuged at 300 g for 10 minutes. Cells were further labeled by secondary anti-
Biotin antibodies. Unlabeled monocytes were collected by pulling out the cell solution 
while in a magnetic field.  
 
             The enriched monocytes were seeded on culture plate coated with 
recombinant CD137-Fc protein or Fc fragment at 4ºC overnight. The monocytes were 
cultured for 7 days and harvested by 10 mM EDTA in  PBS. 1 μg/ml LPS was added 
for the last 24 h to mature the cells. 
  
2.5 3
             Cell proliferation was determined by 
H-thymidine proliferation assay 
3H-thymidine incorporation. Cells were 
pulsed with 0.5 μ Ci of 3
 
H-thymidine (PerkinElmer, Boston, USA) for the last 16 hr 
of the culture period. The cells were then harvested onto a Packard Unifilter Plate 
using a MicroMate 196 Cell Harvester and counted using a TopCount Microplate 




2.6 CFSE proliferation assay 
               Cells were stained with 5 μM CFSE (Invitrogen, Carlbad, USA) in PBS with 
0.1% BSA  at 37 °C for 10 min. Incorporation of CFSE dye was stopped by adding 5 
volumes of ice-cold RPMI medium supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and 100 μg/ml streptomycin and 2.1 Mm L-glutamine and 
incubation on ice for 5 min. Cells were then washed with the same medium and 
centrifuged at 300g for 10 min for three times. Dilution of CFSE dye was determined 
by flow cytometry on Cyan flow cytometer (Dako, Denmark) or BD LSRFortessa cell 
analyzer (BD Bioscience). Mean fluorescence intensity (MFI) of CFSE dye at FITC 
channel was used as measure for cell proliferation. 
 
2.7 Phagocytosis assay 
              Yellow-green fluorescent carboxylated-modified microspheres 
(FluroSpheres, Molecular Probes) were added at a ratio of 50 beads per cell at 37°C in 
the dark. Cells undergoing the same treatment but without the additions of beads 
served as negative controls. After 1 hr incubation, the reaction was arrested by 
addition of 1 ml ice-cold PBS. Cells were then washed in PBS and trypsin-EDTA was 
added to dislodge surface adherent beads. Cells were washed again with PBS and 





The concentrations of IL-10, IL-12p70 , GM-CSF, M-CSF, MCP-1 and IL-1 
beta in cell supernatants were determined by mouse IL-10 (R&D) , IL-12p70 p70 
(R&D), GM-CSF (R&D), IL-1 beta  (Perprotech), M-CSF (Perprotech), G-CSF 
(Perprotech), MCP-1 (Perprotech) according to the manufacturer’s instructions. All 
measurements were done in triplicate. 
 
2.9 Allogeneic mixed lymphocyte reaction 
CD11b+, Ly6G- monocytes were isolated from the femur bones of 6-week 
old BALB/c mice by negative enrichment according to manufacturer’s instruction 
(Stemcell Technologies). 2x105 monocytes per well were cultured in 24-well plates 
that had been precoated with 10 µg/ml of Fc or CD137-Fc. In parallel, cells were 
treated with 100 ng/ml GM-CSF + 25 ng/ml IL-4 (Peprotech) to generate immature 
classical DCs. Maturation of DCs and CD137-treated monocytes was induced on day 
6 by addition of 1 μg/ml LPS (Sigma). Subsequently, cells were harvested by 
incubation with 1x PBS, 10 mM EDTA at RT for 10 min and washed twice with PBS, 
and served as stimulator cells. T cells were isolated from splenocytes of 6-week old 
C57BL/6 mice by magnetic selection using the Pan T cell isolation kit (Miltenyi 
Biotec). 105 T cells were cocultured with stimulator cells at a 10:1 ratio in 96-well 
round bottom plates for 3 days and pulsed with 0.5 μCi 3H-thymidine per well for the 
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last 16 hr. The rate of T cell proliferation was determined with a scintillation counter 
as described in 2.5 (Packard, Meriden, CT, USA).  
 
2.10 Isolation of T cells from splenocytes 
Splenic T cells were isolated by MACS using the mouse Pan T Cell isolation 
kit (Miltenyi Biotec). Briefly, the fresh splenocytes were labeled with a cocktail of 
biotin-conjugated antibodies against CD45R (B220), CD49b (DX5), CD11b (Mac-1), 
and Ter-119 expressed on non-T cells (B cells, NK cells, DCs, macrophages, 
granulocytes and erythroid cells), followed by anti-biotin microbeads. The cell 
suspension was passed through a LS column in a strong magnetic field, and the 
untouched T cells were collected in the effluent. 
 
Splenic CD4+ T cells were isolated by MACS using the CD4 microbeads 
(Miltenyi Biotec). Splenocytes were labeled with microbeads and passed through LS 
column in a magnetic field. Positive selected CD4+
 
 T cells were later flushed out 





2.11 Antibodies and flow cytometry 
Low endotoxin, azide-free anti-mouse CD3 (clone 17A2), CD28 (clone 
37.51), PE conjugated anti-mouse CD11b (clone M1/70), Gr-1 (clone RB6-8C5), 
TER-119 (clone TER-119), B220 (clone RA3-6B2), CD19 (clone 6D5), CD3 (clone 
145-2C11), CD11c (clone N418), F4/80 (clone BM8), CD137 (17B5), CD69 
(H1.2F3), APC conjugated anti-CD3 (17A2), Ly6C (clone HK1.4), Sca-1 (clone D7), 
FITC conjugated anti-CD44, BrdU, CD117 (clone 2B8), PE-Cy7 conjugated anti-
CD62L (MEL-14), Ly6G (clone RB6-8C5), eFluor450 conjugated anti-CD4 (GK1.5), 
eFluor710 conjugated anti-CD8 (53-6.7) and their isotype controls rat IgG2a (clone 
RTK2758), rat IgG2b (clone RTK4530), Armenian hamster IgG (clone HTK888) 
were obtained from eBioscience and Biolegend (San Diego, CA, USA).  
 
2 - 3 × 105 cells were stained with respective fluorochrome-conjugated 
antibodies in PBS containing 0.5% FBS and 0.1% sodium azide (FACS buffer) 
together with mouse FcR blocker (Miltenyi Biotech) for 1 hr at 4°C in the dark. Cells 
were then washed twice and resuspended in 500 µl of FACS buffer. If fixation was 
required, the cells were fixed with 1% PFA for 1 hr at 4ºC. Flow cytometry was 
performed either on a FACSCalibur (BD Biosciences, San Diego, CA, USA) with 
CellQuest data acquisition and analysis software, or on a Cyan flow cytometer (Dako, 
Denmark) with Summit software v4.3. Flow cytometry was also performed using the 
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BD LSRFortessa cell analyzer (BD Bioscience) and analyzed with Flowjo. 
Nonspecific staining was controlled by isotype-matched antibodies.  
 
Countbright Absolute Counting Beads (Invitrogen) were added to samples 
for flow cytometry when calculation of absolute cell number was performed. Cell 
number in each sample was calculated based on following formula: 
 
Figure 2.1 Calculation of absolute cell number. Concentration of cells in the 
sample was calculated based on the ratio of number of cells and counting beads 
acquired in respective gate during flow cytometry.  
 
2.12 Immunohistochemistry 
B. pertussis-infected BALB/c mice or Influenza A (PR8, H1N1) infected or 
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) C57BL/6 mice were sacrificed 
3, 4 and 21 days post-infection for harvesting femurs respectively. Naïve mice were 
used as negative control. The femur bones were harvested, fixed with 10% formalin 
followed by decalcification with 10% EDTA in H2O for 14 days. The decalcified 
bones were fixed and embedded in paraffin. After deparaffinization in Xylene, and 
dehydration in a graded series of alcohol, the slides were pretreated with citrate buffer 
(Dako, Denmark) in a pressure cooker at 109ºC for 15 min, or were incubated in 20 
µg/ml Proteinase K (Sigma Aldrich, St Louis, MO, USA) in PBS at 37 °C for 1 hr for 
48 
 
antigen retrieval. Endogenous peroxidases were inactivated by 3% hydrogen peroxide 
for 15 min. Unspecific staining was blocked by 3% dry milk in PBS for 30 min. 0.5 
µg/ml of biotinylated goat anti-mouse CD137 polyclonal antibody (R&D Systems, 
MN, USA) or its isotype control (biotinylated goat IgG, R&D systems) in TBS were 
used as primary antibodies and hybridized overnight. The secondary Strepavidin-HRP 
(Sigma-Aldrich, St Louis, MO, USA) was added for 30 min, followed by DAB+
 
 
substrate (Dako, Denmark). The entire procedure was carried out at room temperature 
and after each step the samples were washed three times with PBS. Finally, the tissue 
sections were counterstained with hematoxylin (Sigma-Aldrich, St Louis, MO, USA) 
and mounted.  
2.13 Transfer of in vitro activated T cells to WT mice 
WT or CD137-/- splenic T cells were isolated as previously described and 
activated by α-CD3/CD28 antibodies (Biolegend, USA) for 48 h. Cells were stained 
with 5 μM CFSE at 37°C for 10 min. Uptake of CFSE dye was stopped by addition of 
5 volumes of ice-cold RPMI-1640 medium with 10% FBS. Cells were incubated on 
ice for 5 min and washed in completed medium three times. After the wash cells were 
resuspended in PBS at a concentration of 106 cells/ml and intravenously injected into 
mice. 24 hr after the injection, mice were euthanized by CO2 inhalation. Spleen, 
draining lymph node and bone marrow were harvested. Single cells solution of each 
organ was prepared and stained for CD3. Numbers of CFSE+ cells were detected by 
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flow cytometry on a Cyan flow cytometer (Dako, Denmark) with Summit software 
v4.3.. 
 
2.14 Isolation of Lin- progenitor cells from bone marrow and coculture of CFSE-
labeled bone marrow/ Lin-
Lin
 progenitor cells with activated T cells 
- 
Bone marrow cells and Lin
progenitor cells were isolated by magnetic cell sorting using the mouse 
lineage cell depletion kit (Miltenyi Biotec). Briefly, the fresh bone marrow cells were 
labeled with a cocktail of biotin-conjugated antibodies against CD5, CD45R, CD11b, 
Gr-1, Ter-119 and 7-4, followed by anti-biotin microbeads. The cell suspension was 
passed through a LS column in a strong magnetic field and the lineage negative 
progenitor cells were collected in effluent.  
- progenitor cells were resuspended at 106 cells/ml 
in PBS with 0.1% BSA. Cells were stained with 5 μM CFSE, and 105 CFSE-labeled 
bone marrow and Lin- progenitor cells were then cocultured with CD4+ 
 
T cells 
prectivated by CD3 and CD28 antibodies for 48 hr at a ratio of 1:2. On day 6 of 
coculture the cells were harvested and stained for CD4, CD11b, Gr-1, Ly6G, Ly6C 





2.15 Cell Viability Count 
Numbers of viable cells were counted by using Sphero Accucount Blank 
Particles (Spherotech) and 7-AAD (BD Pharmingen) staining on flow cytometry. 
Cells were first stained for 7-AAD and 5 μl of counting beads were added to each 
sample before flow cytometry. Cells were gated for 7-AAD-
 
 population and number 
of cells were calculated. Each sample was performed in triplicates. 
2.16 BrdU Incorporation 
1 mg of BrdU was injected i.p into WT and CD137-/- 
 
mice 6 hr before 
euthanization. The staining of BrdU protocol follows manufacturer’s instruction (BD 
Pharmingen). Briefly, bone marrow cells were fixed and permeabilized by 
Cytofix/Cytoperm Buffer on ice for 30 min. Cells were washed by 1x Perm/Wash 
Buffer. Cells were incubated with Cytoperm Permeabilization Buffer Plus on ice for 
10 min to permeabilized the nucleus membrane. After the wash the cells were refixed 
with Cytofix/Cytoperm Buffer on ice for 5 min. DNA was digested by incubation of 
cells in PBS with 300 μg/ml of DNase for 1 hr at 37°C. Then BrdU incorporated was 
stained by addition of FITC conjugated anti-BrdU antibodies for 20 min at RT. The 




2.17 Microscopy  
Morphological changes of cells were documented by using a Zeiss Axiovert 
40 inverted microscope (Zeiss, Göttingen, Germany) and Canon PowerShot G6 digital 
camera. 
 
Images of IHC stainings were documented using a Leica DM 2000 
microscope, a Leica DFC 490 digital camera, and the Leica application suite (version 
2.8), (Leica Microsystem, Wetzlar, Germany). Four to five representative areas were 
selected from each slides and number of positive cells were counted in each area.  
 
2.18 Colony formation assay 
Bone marrow cells from 3-months and 12-months old mice were harvested as 
previously described. Cells were resuspended in IMDM at the concentration of 1 
million/ml. 300 μl of cell solution were added to 3 ml of Methocult 3434 (Stemcell 
Technologies) for myeloid progenitor detection. 1.1 ml of medium was dispensed to 
treated culture dish and incubated at 37°C for 7 to 10 days. Types of colonies were 
determined based on manufacturer’s instruction. Duplicates of plates were prepared 





Quantitative data are presented as mean ± SD. Statistical significance was 
determined by two-tailed unpaired Student’s t-test or Mann-Whitney Test when 
















Chapter 3 Results 
3.1 CD137L reverse signaling in murine monocytes  
Studies from our laboratory have shown that CD137L reverse signaling 
induces proliferation, activation and differentiation of human and murine progenitor 
cells in vitro (Jiang 2008 a, Jiang et al. 2008 b). In the human cells, crosslinking of 
CD137L also promotes differentiation of peripheral blood monocytes to DCs that 
efficiently elicit allogenic T cell proliferation as well as enhance cytotoxic T cell 
activity (Kwajah and Schwarz 2010). These findings inspired us to test whether 
CD137L reverse signaling has similar influence on murine monocytes. It will be 
beneficial if CD137L can differentiate murine monocytes to DCs as it does in the 
human cells so that it is possible to investigate the efficacy of CD137L-DCs in vivo. 
 
3.1.1 CD137L reverse signaling induces morphological change in murine 
monocytes 
Purified murine bone marrow monocytes were grown on plates that had been 
coated with a recombinant protein (CD137-Fc) consisting of the extracellular domain 
of CD137 fused to the constant domain of human IgG1 (Fc). Wells coated with an 




            In response to CD137L reverse signaling the monocytes attached to the plates, 
spread and formed lamellipodia (Figure 3.1.1), similar as it has been shown for 
human monocytes (Langstein et al., 1998). For comparison classical immature DCs 
differentiation induced by GM-CSF and IL-4 showed cluster formation and a 
substantial proportion of the cells remained in suspension. On the other hand, only a 
few of the Fc-treated monocytes attached to the plate and the majority of the attached 
cells lacked lamellipodia formation. The overall density of cells upon Fc treatment 
was also lower than that upon CD137-Fc treatment.  
 
Figure 3.1.1 CD137-Fc induces morphological change of murine bone marrow 
monocytes. Murine bone marrow monocytes were isolated by negative depletion and 
treated with recombinant CD137-Fc or Fc for 6 days. Classical immature DCs were 
generated by GM-CSF and IL-4 for comparison. Morphology was recorded on day 6 
at 20x (upper panel) and 63x (lower panel). Data were representative of three 






3.1.2 CD137L promotes survival and proliferation of murine monocytes 
Since the cell density in Fc treatment groups appeared to be lower, it was 
possible that crosslinking of CD137L promoted cell survival. Cells were harvested by 
10 mM EDTA in 1x PBS after a 7 day culture period. Dead cells were stained by 7-
AAD and gated out by flow cytometry. Counting beads were added to the samples to 
determine the number of live cells. The data showed that the numbers of live cells in 
the CD137-Fc coated wells were five times higher than those in Fc coated wells 
(Figure 3.1.2.A).   
 
The increased number of live cells resulting from treatment with CD137-Fc 
protein could be the result of prolonged cell survival, induction of proliferation or a 
combination of both effects. Indeed, 3
 
H-thymidine proliferation assay showed that 
CD137L reverse signaling induced a significant proliferation of monocytes while 
control cultures did not proliferate (Figure 3.1.2.B). These data demonstrated that 
similar as in the human cells CD137L reverse signaling induced adherence, 






A                                                  B 
 
Figure 3.1.2 CD137L promotes survival in murine monocytes. Monocytes were 
isolated from bone marrow and treated with CD137-Fc or Fc as previous described. 
(A) Number of viable cells treated by CD137-Fc and Fc. Murine monocytes treated 
by CD137-Fc or Fc were stained by 7-AAD and analyzed by flow cytometry. 
Numbers of viable cells (7-AAD-) were determined using counting beads. (B) 
Proliferation of monocytes measured by 3H thymidine assay. Cells were pulsed with 
0.5 μ Ci 3
 
H-thymidine for 16 hr. Triplicates were performed for each treatment. 
*p<0.05. Data were representative of three independent experiments.  
3.1.3 Costimulatory molecules are absent in CD137-treated monocytes 
In human monocytes CD137L reverse signaling induces strong expression of 
costimulatory molecules including CD80 and CD86 which are further enhanced by 
DCs maturation signals such as LPS and IFN-gamma (Lippert et al., 2008; Ju et al., 
2009, Kwajah and Schwarz 2010).  The presence of costimulatory molecules is a 
strong indication that cells exhibit a DCs phenotype. Hence, the expression of two 
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major costimulatory molecules, CD80 and CD86, was examined on CD137-Fc treated 
monocytes. 
 
  High levels of CD80 (79.5%) and CD86 (58.7%) were expressed by the 
classical immature DCs induced by GM-CSF and IL-4. However, in murine 
monocytes treated by CD137, CD137L reverse signaling only marginally induced 
CD80 and CD86 with percentages of positive cells of 9.6% and 14.8 %, respectively. 
Addition of LPS had no effect on the expression of CD80, but slightly increased the 
level of CD86 to 26.7%. Both costimulatory molecules were expressed at very low 




Figure 3.1.3 Expression of costimulatory molecules in CD137-Fc treated 
monocytes. Murine monocytes were treated with CD137-Fc or Fc for 7 days. Cells 
were matured by LPS for the last 24 h. Murine monocytes treated with GM-CSF and 
IL-4 served as classical immature DCs. Expression of CD80 and CD86 was examined 
by flow cytometry. Open histograms represent cells stained with an isotype control. 
Grey histograms represent cells stained with an antibody specific for the indicated 
surface marker. Numbers in each graph represent percentages of cells stained positive 
for the antigen relative to the isotype control. Data were representative of three 






3.1.4 DCs markers and MHC-II molecule are absent on CD137-treated 
monocytes 
A central property of DCs is their ability to present antigens to T cells. Hence, 
it is important to have high levels of MHC-II, the key antigen presenting molecule on 
the DCs. DCs also express relatively high levels of CD11c which is one of the earliest 
marker used to describe DCs by Steinman (Steinman, 1973; O’Doherty, 1994). 
Therefore, costaining of CD11c and MHC-II provides a first glimpse on the 
phenotype of the cell. As expected, classical mature DCs derived from murine 
monocytes treated with GM-CSF, IL-4 and LPS expressed high level of MHC-II and 
about 46% of the cells expressed both CD11c and MHC-II. However, in spite of the 
substantial upregulated expression of CD11c on CD137-treated monocytes (about 10-
fold, from 3.1 to 29.3%), only a few (6%) of these CD11c+ cells expressed also MHC-
II and only at low levels. As in the case of costimulatory molecule expression, the 
addition of LPS had no effect on enhancing the expression of MHC-II. Compared to 
CD137-Fc treated monocytes Fc control cells were almost devoid of both MHC-II and 




Figure 3.1.4 CD137-treated monocytes lack DCs marker and antigen presenting 
molecules. Expression of CD11c and MHC-II on murine monocytes  were determined 
by flow cytometry. Murine monocytes were treated with Fc or CD137-Fc for 7 days. 
LPS were added to mature the cells for last 24 hours. Murine monocytes treated with 
GM-CSF, IL-4 and LPS were used as classical mature DC controls.  Numbers in the 
graphs represent percentages of cells in each quadrant. Data were representative of 
three independent experiments.  
 
3.1.5 CD137-treated monocytes have a low IL-12p70/IL-10 ratio 
Classical mature DCs have been reported to have a very high IL-12p70/IL-10 
ratio, a typical phenotype of a Th1 immune response because IL-12p70 is the essential 
stimulus for Th1 T cell proliferation and differentiation. On the other hand, IL-10 is 
an immunosuppressive cytokine and typically expressed by regulatory T cells and 
Th2 cells (Blanco et al 2008). Usually inflammatory DCs/macrophages have a high 
IL12/IL10 ratio while regulatory or suppressive DCs/macrophages have a low 
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IL12/IL/10 ratio. Therefore, the levels of IL-12p70 and IL-10 reflect the phenotype of 
CD137-treated monocytes.  
 
As expected classical mature DCs secreted high level of IL-12p70 while the 
level of IL-10 was undetectable (Figure 3.1.5). In the absence of LPS, CD137 
triggered a low level of IL-10 in murine monocytes but not IL-12p70. Both cytokines 
were undetectable in Fc-treated monocytes.  
 
The addition of LPS slightly upregulated IL-12p70 production in Fc-treated 
monocytes but had no effect on CD137-treated monocytes. While stimulation by LPS 
had little effect on expression of CD80, CD86, MHC-II and IL-12p70, it synergized 
with CD137L reverse signaling to reinforce the IL-10 secretion, increasing the 
concentration of this cytokine from less than 100 pg/ml to more than 1600 pg/ml 
(Figure 3.1.5). Although LPS also enhanced IL-10 production in Fc-treated 





Figure 3.1.5 Cytokine production in CD137-treated monocytes. Murine 
monocytes were treated with Fc or CD137-Fc for 7 days. LPS were added to mature 
the cells for last 24 hours. Murine monocytes treated with GM-CSF, IL-4 and LPS 
were used as classical mature DC controls.  Concentrations of IL-10 and IL-12p70 in 
the supernatants of monocytes with indicated treatments were determined by ELISA. 
N.D. indicates that the level of the cytokine is under the detection limit. * p<0.05. 
Data were representative of three independent experiments.  
 
3.1.6 CD137-treated monocytes cannot stimulate T cells in an allogenic mixed 
lymphocytes reaction 
Because CD137L reverse signaling enhances neither costimulatory molecule 
expression nor the production of IL-12p70, the gold-standard to determine the 
phenotype of DCs, allogenic mixed lymphocyte reaction, was employed to assess 




In an allogenic MLR CD137-Fc or Fc treated monocytes from BALB/c 
mice were cocultured with T cells from C57BL/6 mice for 3 days. Classical  
immature DCs and mature DCs were used as negative and positive controls. 
 
Even without maturation by LPS, DCs can stimulate a certain level of T cell 
proliferation, which was increased up to twofold if the DCs were further matured by 
LPS (from 20000 cpm to 40000 cpm). T cell proliferation was hardly detectable in all 
other conditions where monocytes were treated by either CD137-Fc or Fc, regardless 
of addition of LPS.  
 
Figure 3.1.6 Allogenic mixed lymphocytes reaction by CD137-treated monocytes. 
Murine bone marrow monocytes were treated as indicated for 6 days and further 
matured by LPS for the last 24 hr. The treated monocytes were cocultured with T cells 
from C57BL/6 mice at a ratio of 1:10 for 3 days. 3
 
H-thymidine was added for the last 
16 hr and proliferation was measured as count per min (cpm). *p<0.05. Depicted are 
means ± standard deviations of triplicate. Data were representative of three 
independent experiments.  
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3.1.7 CD137L reverse signaling upregulates macrophage markers on murine 
monocytes 
Along the differentiation journey of monocytes during inflammation, the 
cells can become either DCs or macrophages dependent on the signals they receive. 
Since CD137-Fc treated monocytes did not exhibit typical markers and cytokine 
profile of classical DCs, it was investigated whether the cells have taken an alternate 
path to become macrophages. 
 
To answer this question, the expression levels of CD14 and F4/80, two 
markers commonly found on differentiated macrophages, were examined. Staining of 
CD14 and F4/80 showed that CD137-Fc substantially upregulated the expression of 
both molecules compared to Fc treatment on murine monocytes. CD14 was totally 
absent in Fc-treated monocytes but expressed by 59.4% of cells treated with CD137-
Fc. Compared to classical DCs, CD137-treated monocytes had 15% more cells 
expressing CD14. The effect of CD137L reverse signaling in inducing macrophage 
markers became more evident for F4/80, which was upregulated from 51.1% to 80.9% 
in CD137-Fc treated monocytes compared to Fc treatment. As expected, only 18% of 





Addition of LPS slightly enhanced the expression of F4/80 in CD137-Fc 
treated monocytes, bringing up the level by 7% (80.9% to 87.5%). The increase was 
more prominent for CD14, where the expression level was increased by 20% to 
80.9%. However, LPS did not further increase the expression level of either F4/80 or 
CD14 of Fc-treated monocytes. 
 
Figure 3.1.7 CD137 upregulates macrophage markers in monocytes. Murine 
monocytes were treated with Fc or CD137-Fc for 7 days. LPS was added to mature 
the cells for last 24 hours. Murine monocytes treated with GM-CSF, IL-4 and LPS 
were used as classical mature DC controls.  After 6 days of culture, cells were 
harvested and stained for the two macrophage markers, F4/80 and CD14. The 
expression levels were analyzed by flow cytometry. Open histograms represents cells 
stained with isotype controls. Grey histograms represent cells stained with antibodies 
against the indicated surface marker antigen. Numbers in the graphs represent 
percentages of cells that have shifted relative to the isotype controls. Data were 
representative of three independent experiments.  
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3.1.8 CD137-treated monocytes have enhanced phagocytic activity 
One major characteristic that distinguishes classical DCs from macrophages 
is the level of phagocytosis. As the major APCs, DCs have high levels of endocytosis 
but very low levels of phagocytosis (Kwajah and Schwarz, 2010). In macrophages, 
however, the situation is reversed as the core function of macrophages is to clear 
pathogens and debris. To determine whether CD137-treated monocytes were 
macrophages the level of phagocytosis was examined by flow cytometry.  
 
Monocytes treated by CD137-Fc or Fc were given fluorescent beads at 37°C 
for 1 hr. To confirm that the observed phagocytotic activity was not a result of 
random adherence to the cell surface, trypsin was added to the harvested monocytes to 
cleave off beads binding to surface proteins. The percentages of cells that have 
phagocytosized fluorescent beads and numbers of fluorescent beads taken up by each 
cells (expressed as mean fluorescent intensities) were measured by flow cytometry.  
 
Upon treatment by CD137-Fc, monocytes became highly phagocytic as 71.8% 
of the cells have taken up the fluorescent beads while only 51.1% of the Fc-treated 
cells have become phagocytic. Among the phagocytic cells, CD137-Fc treated 
monocytes were on average more phagocytic as their MFI was considerably higher 
than that of Fc treated monocytes (1930 vs 794). 
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Trypsinization significantly reduced the non-specific binding of beads to Fc-
treated monocytes by reducing the percentage of phagocyotic cells from 62.4% to 
51.1%, and the MFI from 2031 to 794. In the CD137-treated monocytes, however, the 
percentage of phagocytotic cells as well as the MFI was hardly affected, meaning that 
the CD137-treated monocytes were truly phagocytic.  
   
 
Figure 3.1.8 CD137L reverse signaling upregulates the phagocytic activity of 
monocytes. Monocytes were treated with CD137-Fc and Fc protein for 6 days. 
Fluorescent beads were added to the culture for 1 hr at 37°C in dark. Monocytes were 
harvested by trypsin and analyzed by flow cytometry. Open histograms represent cells 
that have not internalized the fluorescent beads. Grey histograms represent cells that 
have internalized the fluorescent beads. Numbers in the graphs indicate the 
percentages of cells that have internalized fluorescent beads and mean fluorescent 






3.1.9 CD137-treated monocytes exhibit cytokine profile similar to macrophage 
upon stimulation by LPS 
To confirm the phenotype of CD137-treated monocytes as macrophage, the 
cytokine profile of CD137-treated monocytes was compared to that of bone marrow 
derived macrophage (BMM) generated by M-CSF. Unlike classical DCs, BMM 
typically have a low IL-12p70/IL-10 ratio, particularly when stimulated by LPS.  
 
As shown in Figure 3.1.9 CD137-treated monocytes had a very similar 
cytokine profile as BMM. Without addition of LPS, both cell types had low level of 
IL-10 but no IL-12p70 at all. However, upon the addition of LPS, the level of IL-10 
increased significantly while the level of IL-12p70 remained undetectable.   
 
In the human cells, crosslinking of CD137L on peripheral blood induces 
release of M-CSF to support survival and activation of macrophage. In the case of 





Figure 3.1.9 CD137-treated monocytes exhibit property of macrophage. Murine 
monocytes were treated with Fc or CD137-Fc for 7 days. LPS were added to mature 
the cells for last 24 hours. iDC: classical immature DCs: generated by a 7 day culture 
with GM-CSF + IL-4. DCs: classical mature DCs generated by a 7 day culture with 
GM-CSF + IL-4, and stimulated by LPS for the last 24 h. Mac: BMM generated by a 
7 day culture with M-CSF. Levels of IL-10 and IL-12p70 in the supernatants of DCs, 
macrophages and CD137-Fc treated monocytes were determined by ELISA. N.D: 
non-detectable. Depicted are means ± standard deviations of duplicates *p<0.05. Data 
were representative of three experiments.  
 
3.1.10 CD137L reverse signaling does not induce maturation in murine DCs  
Previous studies have reported that CD137L reverse signaling upregulates 
MHC-II and costimulatory molecules CD86 by more than two fold in cord-blood 
derived DCs in the human cells (Kim, Li et al. 2002). Although treatment of CD137 
induces macrophage instead of DC differentiation in murine monocytes, it remains 




Classical immature DCs were generated by GM-CSF and IL-4 for 6 days in 
vitro. The cells were harvested and stimulated by CD137-Fc or Fc immobilized on 
plates for 24 hr. LPS was used as a positive control for DC maturation. Cells were 
then stained for costimulatory molecules: CD40, CD80 and CD86.  
 
        As expected classical immature DCs treated by LPS upregulated all three 
costimulatory molecules: CD40 (8.9% to 33.7%), CD80 (56.7% to 59.8%), CD86 
(21.0% to 61.0%). However, the levels of costimulatory molecules remained 
unaltered on DCs stimulated by CD137-Fc compared to classical immature DCs 
treated by PBS. The expression of CD40 was only 5.6% in CD137-Fc treated DCs. 
Although CD80 on CD137-Fc treated DCs was similar to mature DCs, the latter one 
had higher expression on a subpopulation of DCs based on the higher MFI. 
Expression of CD86 on CD137-Fc treated DCs was only 22.1% compared to 60.1% 
of mature DCs. The expression levels of all three costimulatory molecules were 
similar between CD137-Fc and Fc-treated DCs. 
 
        It was also reported in previous studies that upon maturation by CD137 protein 
human DCs increased production of proinflammatory cytokines including IL-12p70 
and TNF-alpha (Kim, Li et al. 2002). Examinations of the levels of four 
proinflammatory cytokines, IL-12p70, TNF-alpha, IL-1 and IL-6, in the supernatants 
of CD137-treated murine DCs showed that CD137L reverse signaling was able to 
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induce low levels of IL-12p70, TNF-alpha, and IL-1 in the classical immature DCs. In 
spite of the low level of cytokine release, these concentrations were significantly 
lower than in DCs matured by LPS. CD137 was only one-tenth as effective as LPS in 
inducing IL-12p70 (462.5+145 vs 39.5+10.5 pg/ml) and TNF-alpha (1279.3+40.8 vs 
242+15 pg/ml) release in DCs. Additionally, it completely failed to induce IL-6 
production in immature DCs. 
 
       The low level of costimulatory molecules and proinflammatory cytokines 
suggested that CD137L reverse signaling on murine DCs might induce a low degree 
of activation but the cells remained largely immature. The data were further 
confirmed by allogenic MLR. It shows that the CD137-treated DCs were poor APCs 
because they induced considerably lower level of T cell proliferation than classical 
mature DCs. Most importantly there were no difference in T cell stimulation among 










Figure 3.1.10 CD137-Fc does not mature murine DCs. Classical immature DCs 
from BALB/c mice were generated by GM-CSF + IL-4 for 6 days. Immature DCs 
were harvested by 1x PBS, 10mM EDTA and treated by CD137-Fc and Fc 
immobilized on plate for the last 24 hr. Classical mature DCs were induced by 
addition of 1 μg of LPS for the last 24 h. iDC: Classical immature DC treated with 
PBS. DC: Classical immature DC induced by LPS. (A) Expression of costimulatory 
molecules was determined by flow cytometry. Numbers in the graphs represent the 
percentages of populations that had shifted compared to isotype control (open 
histograms). Cells were stained for CD40, CD80 and CD86 and analyzed by flow 










Figure 3.1.10 (B) Levels of IL-12p70, TNF-alpha, IL-6 and IL-1beta were examined 
in the supernatants of CD137-Fc and Fc-treated DCs. N.D: non-detectable. Depicted 















Figure 3.1.10 (C) Bone marrow derived immature DCs generated from Balb/c mice 
treated with LPS, CD137-Fc or Fc were cocultured with splenic T cells from 
C57BL/6 mice for 3 days. 3
 
H thymidine was added for the last 16 hr and proliferation 
was measured as count per min (cpm). Depicted are means ± standard deviations of 
triplicates. *p<0.05. Data were representative of two independent experiments. 
3.1.11 CD137L reverse signaling on murine monocytes is unique and distinct 
from that by other members of TNF receptors 
Monocytes can differentiate to macrophage after they exit from the 
circulation and enter the tissue during inflammation. Component of extracellular 
matrix such as fibronectin have been shown to elicit differentiation of monocytes to 
macrophage in vitro (Sudhakaran, Radhika et al. 2007). Also, in vitro, surface 
proteins and other biomolecules passively adhere to surfaces through hydrophobic and 
ionic interactions and the resulting attachment can induce low degree of 
differentiation of monocytes to macrophage. It is possible that attachment itself is a 
75 
 
differentiation signal for monocytes, regardless of the material as either ECM or 
culture dish surface. 
 
Since the culture plates are coated with a high concentration of CD137-Fc or 
Fc protein, it may mimic an environment of ECM and the observed differentiation is 
simply a result of random binding of surface proteins to culture plate surface coated 
with protein. To exclude such possibilities, murine monocytes were treated with two 
other recombinant proteins, TNFRI and OX40, from the TNF receptor family which 
may exhibit similar properties as CD137. If the observed differentiation is caused by 
random interactions between surface proteins and culture plate, a similar 
morphological change and differentiation in monocytes should be observed when they 
were treated with TNFRI and OX40.  
 
As shown by light microscopy (Figure 3.1.11A), CD137-Fc induced the 
greatest degree of morphological changes with lamellipodia formation and the highest 
degree of cell density in murine monocytes. TNFRI-Fc could also induce a certain 
level of morphological change in the monocytes and lamellipodia formation but to a 
much lesser extent than CD137-Fc. The cell density also appeared to be lower in the 
TNFRI-treated monocytes. Among all three recombinant proteins, OX40-Fc elicited 
the lowest morphological changes with the majority of the cells adopting a round, 
seemingly undifferentiated morphology.  
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Based on the morphological changes of the treated cells, it was observed that 
the cell density appeared to be the highest in CD137-Fc treatment (Figure 3.1.11B). 
7-AAD staining further confirmed that the CD137-Fc treatment group had the highest 
number of viable cells among all treatment groups even though it was not statistically 
significant higher than TNFRI and OX40.  
 
             Aside from the morphological changes, CD137-Fc, TNFRI-Fc and OX40-Fc 
had also different effects on cytokine production (Figure 3.1.11C). Monocytes treated 
with CD137-Fc , TNFRI-Fc or OX40-Fc protein had distinct cytokine profiles. None 
of the molecules induced IL-12p70 production. TNFRI-Fc treated monocytes had the 
highest level of IL-10 and MCP-1 while OX40-Fc treated monocytes had the lowest 












Figure 3.1.11 Morphological change, survival and cytokine productions of 
murine bone marrow monocytes treated by TNFR family members. 
(A)Monocytes were treated with CD137-Fc, OX40-Fc, TNFRI-Fc and Fc. 
Morphological changes were recorded by light microscopy. Data were representative 














Figure 3.1.11 (B) Numbers of viable cells were determined by 7-AAD staining and 
flow cytometry. Depicted are means ± standard deviations of triplicate measurements. 
Data were representative of two independent experiments. (C) Monocytes were 
treated with CD137-Fc, TNFRI-Fc, OX40-Fc and Fc for 6 days. Concentrations of IL-
12p70, IL-10 and MCP-1 were determined by ELISA. Depicted are means ± standard 






3.2 CD137L reverse signaling induces myelopoiesis during inflammation in vivo 
In Section 3.1 it was shown that CD137L reverse signaling induces 
macrophage differentiation and the effect is caused solely by interaction of CD137 
and CD137L. The data indicate a species difference between human and murine cells 
of more differentiated myeloid cells in response to CD137 stimulation. This finding 
restricts the further usage of murine models for testing CD137L-DCs in vivo.  
 
However, CD137L still remains a potential myeloid differentiating factor 
because the less differentiated progenitor cells show similar response in human and 
murine cells (Jiang et al 2008 a; Jiang et al 2008 b). The response of progenitor cells 
is particularly important during infection due to the urgent need for large number of 
leukocytes to clear pathogen. Understanding the influence of CD137L in 
myelopoiesis especially on progenitor cells will contribute significantly to 
development of biological agents to combat infections. The work shown so far has 
been done in vitro and the high concentration of CD137 recombinant protein used 
simulates a highly inflammatory state. It would be of physiological relevance if a 
similar situation can be recapitulated in vivo. In this section the question whether 






3.2.1 Percentage of myeloid cells during naïve state 
Previously Lee and colleagues have reported that CD137 limits myelopoiesis 
during steady state (Lee  et al. 2008). Examination of the percentages of the major 
myeloid markers CD11b, in the bone marrow of naïve WT and CD137-/- mice 
revealed that during steady state CD137-/- mice indeed exhibited significantly higher 
percentages of myeloid cells. The percentages of CD11b were 5% more in the CD137-
/-
 
 mice than WT mice (Figure 3.2.1). 
Figure 3.2.1 Myelopoiesis during steady state of WT and CD137-/- mice. Bone 
marrow of naïve WT and CD137-/- 
 
mice were stained for CD11b. Each dot represents 
one animal. Mann-Whitney test was performed for statistic. * p<0.05. Data were 
pooled from three independent experiments. Each experiment consisted of at least five 
mice per strains. 
3.2.2 CD137 is upregulated in bone marrow during infection 
         If CD137L reverse signaling plays a role in myelopoiesis during inflammation, 
the level of CD137 must increase in the first place to crosslink the ligand. Although 
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the expression of CD137 on a small population of bone marrow cells of healthy mice 
has been reported by Jiang (Jiang er al 2008), the level is very low. In order to gain a 
better understanding of the function of CD137 in the bone marrow during 
inflammation, the level of CD137 expression in the bone marrow was determined by 
IHC under different infection states, including bacteria and viruses. Naïve mice were 
used as basal control.  
 
Intratracheal infection of C57BL/6 WT mice with 5 PFU Influenza A 
(H1N1/PR8) significantly increased the number of CD137-expressing cells in the 
bone marrow 4 days post-infection as determined by IHC (Figure 3.2.2 A). Similarly, 
nasal infection with 106 CFU M. bovis BCG led to an increase in CD137-expressing 
cells in the bone marrow after 3 weeks (Figure 3.2.2 B). Also, 3 days post-infection 
there were more CD137-expressing cells in the bone marrow of mice that were 
nasally infected with 106 CFU Bordetella pertussis than in the bone marrow of naïve 
mice (Figure 3.2.2 C). The data were quantified by counting cells staining positive 
for CD137 in at least four areas each slide. (Figure 3.2.2 D) Quantification data 
showed that in each infection model, the numbers of CD137+
 
 cells were increased by 








Figure 3.2.2 Increased CD137 expression in bone marrow during infections. (A) 
C57BL/6 mice were infected with 5 PFU of Influenza A virus (H1N1) and femur 
bones were harvested 4 days later. (B) C57BL/6 mice were infected with 106
 
 CFU 







Figure 3.2.2 (C) BALB/c mice were infected with 106 CFU of B. pertussis and femur 
bones were harvested 3 days later. Femur bones were immunohistochemically stained 
for CD137 (brown) using a polyclonal goat anti-CD137 antibody. Goat IgG was used 
as an isotype control. The slides were counterstained with hematoxylin (blue). (D) 
Quantification of number of cells stained positive for CD137 in each slide. 




Expression of CD137 can be found on a wide range of cells, including T 
cells, NK cells, epithelial cells and DCs. Due to the potential role of T cells in 
myelopoiesis in the bone marrow, it is hypothesized that T cell is the major cell 
population that express CD137. In order to demonstrate the wider significance of 
CD137 expression during infections and to characterize the CD137-expressing cells 
as T cells in the bone marrow, WT and CD137
 T cells are expanded in bone marrow during infection 
-/- mice were infected with E. coli or 
administered LPS, a component of the E. coli cell wall. Both bacteria and LPS 
induced lethargy and acute inflammation in the animals. Mice were euthanized 48 hr 
after administration of bacteria and LPS and bone marrow cells were harvested for 
flow cytometry. T cells were identified among bone marrow cells based on size, 
granularity and CD3 expression, and were further subcategorized into helper and 
cytotoxic T cells based on CD4 and CD8 expression, respectively. CD137-/- 
 
mice 
served as background control of CD137 (Figure 3.2.3A).  
Among the bone marrow cells from naïve WT mice no CD137-expressing 
CD8+ T cells and minimal numbers of CD4+ T cells could be detected. In contrast, 
injection of LPS or infection by E. coli increased the percentages of CD137+CD4+ T 
cells significantly by 8.5 fold and 10 fold, respectively (Figure 3.2.3BC). CD137+ 
CD8+ T cells also became detectable but their percentage was relatively low in 
85 
 
comparison to those of CD4+ T cells (Figure 3.2.3BC). The absolute number of 
CD137+ CD4+ and CD8+
About two thirds of the CD137-expressing cells in the bone marrow expressed CD3, 
identifying them as T cells (Fig. 3.2.3 E). These data showed that the majority of the 
CD137
 T cells also increased correspondingly (Figure 3.2.3D).  
+ cells which were present in the bone marrow during inflammatory conditions 
were T cells, predominantly CD4+
 
 T cells. 
CD3+CD137+ cells were also sorted from mice with LPS injection together 
with CD3+CD137- and CD3-CD137+ cells (Fig. 3.2.3 F). Comparison of the cell 
morphology revealed that CD3+CD137+ cells had a round morphology that was 
similar to the CD3+CD137- cells, of which the majority was T cells. In the CD3-
CD137+ 
 











Figure 3.2.3 Identification of the CD137-expressing bone marrow cells (A) Gating 
strategy: Lymphocytes among total bone marrow cells were gated based on forward 
scatter (FSC) and side scatter (SSC). T cells were identified by CD3 expression, and 
were further subdivided by CD4 and CD8 staining. 100000 CD3+
 
 T cells were 
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Figure 3.2.3 Identification of the CD137-expressing bone marrow cells (B) 
C57BL/6 WT mice were injected with 106 CFU E. coli or 100 µg LPS, and bone 
marrow cells were isolated 48 hr later. The cells were stained for CD3, CD4, CD8 and 
CD137. Bone marrow cells of naïve mice were used as controls. Numbers in each 
square represent percentages of CD137+ T cells among the total bone marrow cells. 
(C, D) Quantification of percentages (C) and absolute numbers (D) of CD4+ and 
CD8+ T cells among CD137+ T cells and CD137- T cells. Depicted are means ± SD of 








Figure 3.2.3 Identification of the CD137-expressing bone marrow cells (E) 
Percentage of CD3+ T cells among CD137+ cells in the bone marrow. (F) 
CD3+CD137-, CD3+CD137-, CD3+CD137-
 
 cells were sorted from mice with LPS 
injection. Cells were cultured in RPMI with 10% FBS. Morphology was recorded on 
third day of culture. Arrow: Cells with macrophage-like morphology. Data were 
representative of two independent experiments. 
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3.2.4 In vitro activated T cells that express CD137 can home to bone marrow and 
other lymphoid organs 
Since the majority of the CD137-expressing bone marrow cells that increased 
in numbers during infection are T cells, it is hypothesized that they migrate to the 
bone marrow from the site of infection or inflammation or from the draining lymph 
nodes. Therefore, the migratory ability of activated, CD137-expressing T cells from a 
site of inflammation to the bone marrow was investigated. 
 
Splenic T cells were isolated from WT and CD137-/- mice and activated 
with anti-CD3 and anti-CD28 antibodies for 48 h. More than 30% of the activated 
WT T cells expressed CD137 (Figure 3.2.4A). The cells were then labeled with 5 μM 
CFSE and injected i.v. into WT mice. Bone marrow cells, splenocytes and draining 
lymph node cells were analyzed 24 hr after the injection. WT naïve mice were used as 
a negative control. Before injection the expression of CD137 as well as the activation 
markers CD44, CD62L and CD69 were examined (Figure 3.2.4B). These markers are 
known to be upregulated in activated T cells and essential for T cells migration. 
CD62L, also known as L-selectin, was slightly upregulated in CD137-/- activated T 
cells compared to WT (43.7% vs 31.5%). However, no difference was found in the 
expression levels of CD44 and CD69 between activated WT and CD137-/-
 
 T cells.  
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Migration of T cells to lymphoid organ was done by detecting CFSE+ cells 
using flow cytometry (Figure 3.2.4C). Data showed that WT and CD137-/- activated 
T cells were able to migrate to the bone marrow as well as to secondary lymphoid 
organs such as spleen and lymph nodes. The efficiency of T cell migration was 
significantly higher to the spleen than to the bone marrow regardless of the origin of 
the T cells as the absolute cell number of CFSE+ T cells in the spleen was almost 6 
fold higher than that in the bone marrow for both activated WT and CD137-/- T cells. 
The number of activated T cells homing to the bone marrow was similar for the two 
strains both in percentages and absolute cell numbers (Figure 3.2.4DE). 
Unexpectedly, CD137-/-
A 
 T cells had a higher efficacy of homing to the spleen than 
WT T cells.  
 
Figure 3.2.4 Migration of activated, CD137-expressing T cells to the bone 
marrow. Splenic T cells were isolated from WT and CD137-/- mice, activated by anti-
CD3 and anti-CD28 antibodies for 48 hr, and labeled with CFSE. (A) Expression of 








Figure 3.2.4 (B) Expression of homing markers was determined by flow cytometry. 
Isotype: hatched. WT: dark line. CD137-/-: grey line. Numbers indicate percentages of 
positive cells relatively to isotype control. Data were representative of two 
independent experiments. (C) Activated WT or CD137-/- T cells were injected i.v. into 
WT mice. 24 hr later mice were euthanized and the number of CFSE+, CD3+ cells that 
migrated to the bone marrow, spleen and lymph nodes were analyzed by flow 
cytometry. 100000 CD3+ T cells were acquired for each sample.Numbers in graph 
insets represent percentages of CFSE+, CD3+
 
 cells among total lymphocytes. Each 
treatment group consisted of 5 mice. 
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Figure 3.2.4 (D) Percentages and (E) absolute numbers of CFSE+, CD3+
 
 cells that 
have migrated to bone marrow, lymph node and spleen. *p<0.05. Statistical analysis 
was done by two-tailed unpaired Student’s t-test. Data were representative of three 
independent experiments.  
3.2.5 Activated CD4+
Having demonstrated that activated, CD137
 T cells induce bone marrow cells proliferation through 
CD137L reverse signaling 
+ T cells can migrate from 
peripheral tissue to the bone marrow the next aim was to test whether the CD137+ T 
cells can contribute to myelopoiesis. The major focus was on CD4+ T cells since they 
rather than CD8+ T cells constituted the majority of CD137+
 
 T cells in the bone 
marrow of mice during peritonitis (Figure 3.2.2).  
CD4+ T cells were isolated from splenocytes of WT and CD137-/- mice by 
magnetic cell sorting, and were activated with 5 µg/ml of immobilized anti-CD3 and 
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anti-CD28 antibodies. 48 hr later WT bone marrow cells which have been labeled 
with CFSE were added to the activated CD4+ T cells at a ratio of 2:1. After 6 days of 
coculture the proliferation of bone marrow cells was determined based on CFSE 
dilution. The CFSE MFI of bone marrow cells cocultured with WT or CD137-/- CD4+ 
T cells was 267.3 and 775.7, respectively, demonstrating that WT CD4+ T cells 
induced a much stronger proliferation of bone marrow cells than CD137-/- CD4+ T 
cells (Figure 3.2.5 AB). This increased proliferation was accompanied by an increase 
in the percentage of CD11b+ bone marrow cells (92.8 ± 1.8% versus 67.8 ± 16. 7%) in 
the cocultures with WT CD4+ T cells (Figure 3.2.5 CD). These data indicated that 
CD137 expressed on CD4+ 
 
T cells induced bone marrow cell proliferation and 
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Figure 3.2.5 CD137-experssing CD4+ T cells promote myelopoiesis in vitro. 
CD137-expressing CD4+ T cells promote myelopoiesis in vitro. WT and CD137-/-
 CD4+ T cells were isolated from spleens and were activated for 48 h with 5 µg/ml α-
CD3/CD28 antibodies. WT bone marrow cells were isolated and labeled with CFSE, 
and cocultured with activated CD4+ T cells at a ratio of 1:2. After 6 days of coculture, 
cells were harvested and CD11b expression was quantified by flow cytometry. Equal 
numbers of CFSE+ cells were acquired for each sample. (A) CFSE dilution of bone 
marrow cells. The dark and grey lines represent the dilution of CFSE of bone marrow 
cells cocultured with WT or CD137-/- CD4+ T cells, respectively. (B) Quantification 
of (A) from quadruplicate measurements. Depicted are means of mean fluorescent 
intensities (MFI) ± SD. (C) Expression of CD11b on CFSE+ bone marrow cells. The 
dark and grey lines represent CD11b staining of bone marrow cells cocultured with 
WT or CD137-/- CD4+ T cells, respectively. (D) Quantification of (C) from 
quadruplicate measurements. Depicted are means of percentages of CD11b+ 
 
cells ± 
SD. Data were representative of two independent experiments. 
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3.2.6 Activated CD4+ T cells induce Lin-
Bone marrow cells include both Lin
 progenitor cell proliferation through 
CD137L reverse signaling 
- progenitor cells and monocytes, both 
of which have been demonstrated to proliferate and differentiate in response to 
recombinant CD137 stimulation. Lin-
 
 progenitor cells are of particular interest 
because of their ability to give rise to downstream myeloid cells. 
To examine the response of Lin-progenitor cells to T cell stimulation with or 
without the interaction of CD137 and CD137L, Lin- progenitor cells were isolated 
from bone marrow cells of WT and CD137L-/- mice by negative selection. The cells 
were CFSE labeled before being cocultured with activated WT and CD137-/- 
 
T cells. 
Cells were stained for CD4, CD11b and Gr-1. Progenitor cells and activated T cells 
were separated by CD4 expression and CFSE intensity (Figure 3.2.5 A)  
Similar to the results observed using total bone marrow cells, when CD137L 
was absent from the progenitor cells, cells displayed reduced proliferation as shown 
by MFI of CFSE dilution (328 vs 476) (Figure 3.2.5 B). On the other hand WT T 
cells induced a higher degree of cell proliferation in progenitor cells than CD137-/- T 
cells (328 vs 413) (Figure 3.2.5 C), suggesting that the presence of CD137 on the 
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stimulator cells or the presence of ligand on the responder cell are essential for 
CD137L-mediated myelopoiesis.  
 
       Costaining of CD11b or Gr-1 together with CFSE labeling of the progenitor 
showed that although both WT and CD137L-/- progenitor could proliferate when 
cocultured with activated T cells, CD137L reverse signaling clearly favored myeloid 
differentiation as more proliferating WT progenitor cells belonged to the CD11b and 
Gr-1 compartment compared to CD137L-/- progenitor cells (Figure 3.2.5 EF). 
CD137L-/- progenitor cells cocultured with CD137-/- T cells had the lowest level of 
myeloid differentiation of all groups and only one third of the CD137L-/-
 
 progenitor 
cells cocultured with WT T cell expressed CD11b (18.0% vs 46.0%, Figure 3.2.5 F).  
       In addition to surface bound CD137, myeloid differentiating factors such as GM-
CSF, M-CSF and G-CSF may synergize to reinforce myelopoiesis. The levels of these 
three cytokines in the supernatants of the coculture were tested. Surprisingly, 
cocultures with CD137-/- 
 
activated T cells showed a significantly higher amount of 
GM-CSF and G-CSF than cocultures with WT activated T cells in spite of the reduced 
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Figure 3.2.6 CD137-experssing CD4+ T cells promote myeloid lineage 
proliferation and differentiation of Lin- progenitor cells in vitro. Lin- progenitor 
cells were isolated from WT and CD137L-/- mice, labeled with CFSE, and were 
cocultured with activated WT or CD137-/- T cells. On day 6, cells were harvested and 
stained for CD4, CD11b and Gr-1. Equal numbers of CFSE+ cells were acquired for 
each sample. (A) Cells were first gated on forward and side scatter. CD4+ T cells were 
gated out based on low CFSE fluorescence and high CD4 expression. Progenitor cells 
were gated based on high CFSE intensity. (B,C) Proliferation of WT (dark lines) or 
CD137L-/- (grey lines) progenitor cells cocultured with WT or CD137-/- 
 
activated T 







Figure 3.2.6 (D) Means ± SD of 5 repeats of (B and C). (E) Expression of CD11b and 
Gr-1 on CFSE-labeled WT or CD137L-/- progenitor cells that had been cocultured 
with WT or CD137-/- activated CD4+ T cells. Numbers represent percentages of 
CD11b+ or Gr-1+ cells among total CFSE+
 








Figure 3.2.6 (F) Quantification of percentages of CD11b+ and Gr-1+
 
 cells from (E). 
(G) GM-CSF and G-CSF concentrations in supernatants of cocultures. Depicted are 
means ± SD of 5 measurements. * p<0.05. Statistical analysis was done by two-tailed 
unpaired Student’s t-test. Data are representative of two independent experiments.  
3.2.7 Activated WT and CD137-/-
It is surprising that CD137
 T cells do not differ in GM-CSF production 
-/- T cells actually secrete more GM-CSF and G-
CSF into the supernatant than WT T cells when cocultured with progenitor cells. The 
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differences can be due to two causes: 1. the hyperproliferation of CD137-/- T cells; 
and/or 2. the absence of CD137 on T cells upregulates of GM-CSF. To investigate 
whether CD137 inhibits GM-CSF production in T cell, supernatants of WT and 
CD137-/- T cells were tested for GM-CSF levels. GM-CSF production by either total 
T cells or CD4+
 
 T cell after activation by anti-CD3 and anti-CD28 antibodies was not 
affected by the presence of CD137 (Figure 3.2.7 A ). M-CSF was not detectable in all 
conditions. 
Although expression of CD137 in vitro does not give an advantage to the T 
cells in regards to GM-CSF production, it may enhance the levels of GM-CSF in vivo. 
CD3+CD137- and CD3+CD137+
 
 T cells sorted from mice injected with LPS were 
cultured for 3 days before harvest of the supernatants. There was no significant 
difference between the two T cell populations in GM-CSF production, suggesting that 
in vivo CD137 did not enhance levels of GM-CSF(Figure 3.2.7 B). 
The data suggested that CD137 did not influence the production of GM-CSF 
by T cells. The difference observed in the supernatants of cocultures with progenitor 
cells was probably a result of hyperproliferating CD137-/-
 








Figure 3.2.7 Expression of CD137 does not affect levels of GM-CSF expression. 
(A) Levels of GM-CSF were measured in activated WT and CD137-/- total or CD4+
 
 
T cells by ELISA. Each sample was done in triplicates. (B) Levels of GM-CSF were 
measured in supernatants of sorted cells from WT mice after receiving LPS injection. 




3.2.8 CD137L reverse signaling enhances primary myelopoiesis during acute 
peritonitis  
So far it has been shown that in vitro CD137+ CD4+ T cells can directly 
induce myelopoiesis in Lin- progenitor cells. However, the effect has yet to be 
demonstrated in vivo. A model of acute peritonitis using E.coli was employed in order 
to determine whether under inflammatory situation CD137L reverse signaling can 
induce myelopoiesis in vivo too. To ensure that any increase in myeloid cell number 
was due to local proliferation but not trafficking of cells in and out of bone marrow 
compartment, the newly emerging cells were labeled by BrdU. 106 CFU E. coli were 
injected i.p. into WT and CD137-/-
 
 mice. After 48 hr when acute peritonitis had 
developed the mice were sacrificed but 6 hr prior to euthanization 1 mg BrdU per 
mouse was injected. 
As in the case of infection with Influenza, B. pertussis and BCG (Figure. 
3.2.1 ABC) infection with E. coli also led to an increase in the number of CD137-
expressing cells in the bone marrow (Figure 3.2.2 B). The percentages of 
proliferating (i.e. BrdU+) CD11b+ /Gr-1+ cells (Figure 3.2.8 ABC) were significantly 
enhanced in the bone marrow of WT compared to CD137-/- mice. Also the absolute 
numbers of proliferating CD11b+ and Gr-1+ cells in the bone marrow were 
significantly higher in the WT than in the CD137-/- mice (Figure 3.2.8 D). This 
increased proliferation of myeloid cells resulted in an increased percentage (Figure 
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3.2.8 E) and total number (Figure 3.2.8 F) of CD11b+ and Gr-1+
 
 cells in the bone 
marrow of WT mice.  
Extramedullary myelopoiesis in the spleen was also examined. Both the 
percentage and the number of proliferating CD11b+ /Gr-1+ cells in the spleen were 
much lower than that of bone marrow. The absence of CD137 did not influence 
extramedullary myelopoiesis as no difference was detected between WT and CD137-/-







Figure 3.2.8 CD137L reverse signaling enhances primary myelopoiesis during 
acute peritonitis. C57BL/6 WT and CD137-/- mice were injected i.p. with 106 CFU 
E. coli. Mice were sacrificed after 48 hr. 6 hr prior to the euthanization, 1 mg BrdU 
was injected i.p. per animal to label proliferating bone marrow cells. Equal numbers 
of bone marrow cells were acquired for each sample. (A-F) Bone marrow cells were 
stained for CD11b and BrdU (A), or for Gr-1 and BrdU (B) and analyzed by flow 
cytometry. Counting beads (Invitrogen) were added to determine absolute cell 
numbers. Three mice per strain were analyzed. Percentages (C) and absolute numbers 
(D) of proliferating CD11b+, BrdU+ and Gr-1+, BrdU+ cells in the bone marrow. 
Percentages (E) and absolute numbers (F) of total CD11b+ and Gr-1+
 








Figure 3.2.8 (G-L) Splenocytes were stained for CD11b and BrdU (G), or for Gr-1 
and BrdU (H). Percentages (I) and absolute numbers (J) of proliferating CD11b+, 
BrdU+ and Gr-1+, BrdU+ cells in the spleen. Equal numbers of splenocytes were 
acquired for each sample. Percentages (K) and absolute numbers (L) of total CD11b+, 
BrdU+ and Gr-1+, BrdU+
 
 cells in the spleen. Data were representative of three 





3.3 CD137L reverse signaling maintains myelopoiesis during aging 
Having demonstrated that CD137L reverse signaling is essential for 
myelopoiesis during acute inflammation, the next question asked is whether CD137L 
plays a role in promoting myelopoiesis during chronic inflammation, for example, 
aging. Hematopoiesis is strongly skewed towards myelopoiesis during aging while 
lymphopoiesis is much reduced. Identifying CD137L as a contributing factor in 
immuneaging will help to devise novel therapeutic tool to intervene with age-related 
hematopoietic disease.  
 
3.3.1 Numbers of myeloid cells are increased in WT during aging, but not in 
CD137-/- and CD137L-/-
Two major proliferating myeloid populations in the bone marrow that are 
steadily derived from progenitor cells are granulocytes and monocytes. To better 
determine the level of myelopoiesis, granulocytes and monocytes were categorized by 
the differential expression of Ly6G and Ly6C: granulocytes as CD11b
 mice 
+Ly6G+Ly6C+ 
and monocytes as CD11b+Ly6G-Ly6C+. Gender-matched 3-month and 12-month  WT, 
CD137-/- and CD137L-/- 
 
mice were sacrificed and bone marrow cells were stained for 
CD11b, Ly6G and Ly6C. Granulocytes and monocytes were grouped based on the 
expression of Ly6G and Ly6C (Figure 3.3.1A).   
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Percentages of granulocytes and monocytes in 3-month mice did not differ 
significantly among the 3 strains. As the animals aged, percentages of granulocytes of 
12-month WT mice were significantly increased compared to 3-month mice from 27.3% 
to 34.7%, corresponding to previous studies that aging led to an increase of myeloid 
cells (Linton and Dorshkind 2004, Gruver et al. 2007)(Figure 3.3.1B). However, the 
percentages of granulocytes of 12-month CD137-/- and CD137L-/-
 
 mice remained 
unchanged. On the other hand percentages of monocytes were not affected by aging in 
any of the three strains (Figure 3.3.1B). 
Change in percentages could be caused by altered frequencies of other cell 
populations such as B cells in the bone marrow. To better determine the change of 
myeloid populations, absolute cell numbers of granulocytes and monocytes in the 
bone marrow were calculated. Similar to the change of percentages, a significant 
increase of 1.5 fold in the number of granulocytes was detected in 12-month WT mice 
compared to the 3-month control. However, the numbers of granulocytes again 
remained unchanged in both 12-month CD137-/- and CD137L-/- mice. While the 
percentage of monocytes remained similar in the aged animals across the 3 strains, a 
significant increase was observed in the absolute cell number of monocytes where 
WT mice have almost twice the number of cells as the animal age while CD137-/- and 
CD137L-/-
 







Figure 3.3.1 Aged CD137-/- and CD137L-/- mice have reduced myelopoiesis in the 
bone marrow compared to WT. 3-month and 12-month WT, CD137-/- and CD137L-
/- mice were euthanized and bone marrow cells were stained for CD11b, Ly6G and 
Ly6C. Equal numbers of bone marrow cells were acquired for each sample. (A) 
Gating strategy of granulocytes (CD11b+Ly6G+Ly6C+) and monocytes 
(CD11b+Ly6G-Ly6C+
 
) in the bone marrow. (B). Percentages of granulocytes and 







Figure 3.3.1 (C) Absolute cell numbers of granulocytes and monocytes in the bone 
marrow. Each group consisted of at least 5 mice. Data were representative of two 
independent experiments. *p<0.05. 
 
3.3.2 CD4+ 
Compared to acute peritonitis where mice experience a rapid induction of 
inflammation, aging is a chronic inflammatory process induced by environmental 
factors (Wang and Wagers 2011, Woolthuis et al. 2011). It is wondered whether 
during this relatively slow inflammatory process CD137
T cells are increased in bone marrow of aged mice. 
+
 
 T cells will be also 
increased in the bone marrow similarly as during infection. 
Bone marrow cells were isolated from 3-month and 12-month WT, CD137-/- 
and CD137L-/- mice and stained for CD3, CD4, CD8 and CD137. CD137-/- mice 
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served as a negative control for the background staining of CD137 (Figure 
3.3.2ABC).   
 
            As shown previously, there were very few CD137+ T cells in the bone 
marrows at the steady state in young mice. As the WT mice aged, surprisingly, there 
was no significant increase of CD137+ T cells either in absolute cell numbers for both 
CD4+ and CD8+ T cells in WT mice. However, a significant increase in the absolute 
cell number of CD137+ CD4+ T cells was noted in 12-month CD137L-/- mice in spite 
of the reduced myelopoiesis. The number of CD137+ CD4+ T cells was 6 times higher 
in 12-months CD137L-/-
 
 mice than in WT mice and in their younger controls (Figure 
3.3.2B). 
It was also wondered whether the CD137- T cells populations were altered 
during aging because a general increase of polyfunctional memory T cells have been 
reported to accumulate in human bone marrow (Herndler-Brandstetter et al. 2011, 
Herndler-Brandstetter et al. 2012). A general increase in CD137- CD4+ T cells was 
observed in all three strains of mice with the number of cells doubling over 12 months. 
However the absence of either CD137 or CD137L did not affect the number of 
CD137- CD4+ T cells (Figure 3.3.2F).. 
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No significant change was observed in CD8+
A
 
 T cells, regardless of expression 
of CD137 (Figure 3.3.2G). 
B 
 
Figure 3.3.2 Increased number of CD4+ T cells in aged mice. Bone marrow cells 
were isolated from 3-months and 12-months old WT, CD137-/- and CD137L-/- mice 
and stained for CD3, CD137, CD4 and CD8. Absolute number of cells were 
determined by addition of CountBright beads (Invitrogen). (A) Gating strategy of 
CD137+ T cells. (B) Illustration of CD137+ CD4+ T cells in 3-month and 12-month 





D                                                  E 
 
Figure 3.3.2 (C) CD137+ CD8+ T cells in 3-month and 12-month mice of WT, 
CD137-/-, CD137L-/- mice. (D, E) Absolute cell number of CD137+
 
 T cells in 3-
months and 12-months old mice.  
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F                                                          G 
 
Figure 3.3.2 (F, G) Absolute cell numbers of CD137- CD4+/CD8+
 
T cells. Each group 
consisted of at least 5 mice. *p<0.05. Data were represenatative of two independent 
experiments.  
3.3.3 Increased numbers of myeloid progenitor cells in the absence of CD137 
The major cell populations that may give rise to mature differentiated 
granulocytes and monocytes in the bone marrow in response to environmental stimuli 
are the HSCs and myeloid progenitor cells. To investigate whether these two 
populations are affected by the absence of CD137L reverse signaling during aging, 
their numbers were examined in 3-months and 12-months WT, CD137-/- and 
CD137L-/-
 
 mice.  
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Bone marrow cells isolated from the 3-months and 12-months WT, CD137-/- , 
CD137L-/-
 
 mice were stained for lineage marker (CD3, CD19, B220, Ter-119, CD11b, 
Gr-1, CD11c, F4/80), Sca-1, CD117 (c-kit) and IL-7R. For the simplicity, 
hematopoietic stem cells were termed KSL. Categorization of KSL and myeloid 
progenitor cells were based on the expression of Sca-1 and CD117 (Figure 3.3.3A)  
The data showed that KSL accumulated during the aging process in both 
CD137-/- and CD137L-/- 
 
mice, with significantly higher number than 12-months WT 
mice. On the other hand, surprisingly the number of KSL in12-months WT mice was 
unaltered compared to 3-months WT mice (Figure 3.3.3 B). 
Similarly the downstream myeloid progenitor cells showed a significant 
increase in absolute cell numbers in the 12-months CD137-/- and CD137L-/- mice. The 
increment is particularly evident in CD137L-/- mice where a 2 fold difference was 
observed between 12-months WT and CD137L-/-
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Figure 3.3.3 Increased number of myeloid progenitor cells in aged CD137-/-  and 
CD137L-/- mice. Bone marrow cells were isolated from 3-months and 12-months old 
WT, CD137-/- and CD137L-/- mice and stained for the lineage marker, IL-7R, CD117 
and Sca-1. Cells were first gated on progenitor cell region based on forward and side 
scatter. Then Lin-IL-7R- cells were gated out for analysis of myeloid progenitor cells 
(CD117+Sca-1-) and KSL (CD117+Sca-1+). Absolute numbers of cells were counted 
by addition of CountBright beads (Invitrogen). (A) Gating strategy of KSL and 
myeloid progenitor cells. (B) Absolute cell number of KSL and (C) myeloid 
progenitor cells in 3-months and 12-months mice. Each group consisted of 3 mice. 
Data were representative of two independent experiments. *P<0.05. 
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3.3.4 Increasing colony forming units of myeloid lineage of 12-month CD137-/- 
and CD137L-/-
To further confirm that the absence of CD137 or CD137L leads to increasing 
numbers of myeloid progenitor cells, colony forming unit assays were performed to 
assess the number of colony forming unit (CFU) of myeloid lineage in the bone 
marrow of 3-months and 12-months mice.  
 mice 
 
Three types of colonies, CFU-Granulocytes (CFU-G), CFU-Macrophage 
(CFU-M), CFU-Granulocyte/Macrophage (CFU-GM) were detected in 
Methocult3434 (Stemcell Technologies). Types of colonies were determined based on 
the morphology according to manufacturer’s instruction (Figure 3.3.4 A). 
 
The most abundant type of CFU detected was the CFU-GM which contained 
progenitor cells with potential for granulocytes and monocytes. In the 3-month age 
group, CD137-/- and CD137L-/- mice had small but significant increase in the number 
of CFU-GM than WT, corresponding to data previously reported (Kwon, 2002). As 
the mice aged CFU-GM of CD137-/- and CD137L-/- mice continue to increase 
compared to WT. Again 12-months CD137L-/- mice have the highest number of CFU-





mice also had a significant increase but to a lesser degree. WT mice had the lowest 
increase in the number of CFU-GM (Figure 3.3.4 B).  
CFU-G and CFU-M represent progenitor cells with even more restricted 
differentiation potential that can only develop into granulocytes or monocytes. WT 
and CD137L-/- mice showed significant increases in CFU-G as the animals aged. A 
similar pattern was observed in the CD137-/-
A 
 mice although no statistical significance 
was detected. No clear pattern of change was observed for CFU-M in all three strains 
regardless of the age.  
Figure 3.3.4 Increased number of colony forming units in aged CD137-/- and 
CD137L-/-
 
 mice. Colony forming units (CFU) were detected on the frequency of 0.1 
million of total bone marrow cells. (A) Morphology of CFU- 







Figure 3.3.4 (B) Number of CFU per 0.1 million cells. Each group consisted of at 






3.3.5 CD137+ CD4+ T cells enhance myeloid cell differentiation of aged Lin-
 
Previously it has been shown that CD137
progenitor cells 
+ CD4+ T cells can induce 
differentiation of Lin-
 
 progenitor cells from young mice. It is asked whether CD137L 
reverse signaling is also essential for the aged progenitor cells to differentiate to 
myeloid lineage.  
Lin- progenitor cells were isolated from bone marrow cells of 12-months WT 
and CD137L-/- mice. The progenitor cells were labeled with CFSE before being 
cocultured with activated WT CD4+ T cells for 6 days. To better separate the two 
populations, T cells were further stained for CD4. Percentages and absolute cell 
numbers of CD11b+, Ly6G+ and Ly6C+ cells were analyzed in the CFSE+CD4-
 
 
population (Figure 3.3.5A). 
When cocultured with activated CD4+ T cells, 60% of WT progenitor cells 
expressed CD11b+ cells in the CFSE+ population while only 35% of CD137L-/-
 progenitor cells became positive for CD11b (Figure 3.3.5B). With a change close to 
two fold WT progenitor cells clearly had a higher propensity of differentiating to 
myeloid cells than CD137L-/- progenitor cells. The two other myeloid markers, Ly6G 
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To determine that the observed change in frequency of myeloid cells was not 
due to apoptosis of other cell populations, the absolute number of CD11b+, Ly6G+ and 
Ly6C+ cells were calculated. Similar differences was also detected in terms of 
absolute cell numbers where WT progenitor cells had greater numbers of CD11b+, 
Ly6G+ and Ly6C+ cells than CD137L-/-
 
 progenitor cells (Figure 3.3.5C). 
Costaining of CFSE and myeloid markers showed that although WT and 
CD137L-/- progenitor cells can equally proliferate in response to activated T cells, WT 
progenitor cells clearly have a preference of differentiating to the myeloid lineage 
compared to CD137L-/-
 












Figure 3.3.5 Increased differentiation and proliferation of myeloid cells of aged 
WT progenitor cells. Lineage- progenitor cells labeled with CFSE were isolated from 
12-months WT and CD137L-/- mice and cocultured with activated WT CD4+ T cells 
at a ratio of 1:2 for 6 days. Cells were then harvested and stained for CD4, CD11b, 
Ly6G and Ly6C. Countbright beads were added to calculate the absolute cell numbers. 
Equal numbers of CFSE+ cells were acquired for each sample. (A) Gating strategy of 
identifying CD4+ T cells and CFSE labeled progenitor cells. (B) Percentages of 







Figure 3.3.5 (C) Absolute numbers of CD11b+, Ly6G+ and Ly6C+ in CFSE+ 
population. (D) CFSE dilution of CD11b+, Ly6G+ and Ly6C+
 
 cells. Quadruplicates 
were performed for each treatment group. Data were representative of two 




Chapter 4 Discussion 
In the last section, the role of CD137L reverse signaling in promoting 
myelopoiesis has been demonstrated in acute and chronic inflammation models. This 
section will focus on discussing the potential mechanism underlying the CD137L-
mediated myelopoiesis and attempt to resolve conflicts of data reported from various 
research groups.  
 
4.1 Species difference of CD137L reverse signaling between human and murine 
monocytes 
4.1.1 Can CD137L induce DC differentiation in murine monocytes? 
        It was recently reported that CD137L signaling induces differentiation of 
peripheral blood human monocytes to inflammatory DCs, and that these CD137L-
DCs were more potent than classical DCs generated by GM-CSF + IL-4 and matured 
by LPS + IFN-γ (Kwajah and Schwarz 2010). The CD137L-DCs were particularly 
efficient in inducing cytotoxic CD8+ T cell expansion (Kwajah and Schwarz 2010). 
Similar findings were reported by another group showing that CD137L reverse 
signaling synergized with IL-4 to induce DC differentiation from human monocytes 
(Ju, Ju et al. 2009). The above data became the driving force for developing murine 
CD137L-DCs to investigate their T cell stimulatory effect in vivo. DCs have been the 
long-time tool for immunotherapy and it has been shown that successful rejection of 
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tumors largely depends on effective antigen presentation by DCs (Diamond, Kinder et 
al. 2011, Fuertes, Kacha et al. 2011, Palucka and Banchereau 2012). DCs with a 
higher potency would be expected to enhance the efficacy of immunotherapy. One 
major advantage of CD137L-DC over classic DC is that only one recombinant protein 
is required for the ex vivo expansion which reduces variables introduced. The 
generation of the murine equivalent of the human CD137L-DCs promises to allow 
characterization of CD137L-DCs in murine models and thereby obtaining more 
relevant in vivo data on the potency of CD137L-DCs. 
 
Based on the reports with human CD137L-DCs it was hypothesized that 
CD137L reverse signaling should be able to induce differentiation of murine 
monocytes to inflammatory DCs. Indeed, the phenotypical response, i.e. increased 
attachment, morphological changes and induction of proliferation are identical 
between monocytes from the two species. But surprisingly, CD137 treatment fails to 
generate inflammatory DCs from murine monocytes as marked by the absence of 
costimulatory molecules and MHC-II, low levels of IL-12p70 and the inability to 
stimulate allogenic T cell proliferation. 
 
In the human cells, CD137L-DC does not require further maturation by LPS 
(Kwajah and Schwarz 2010). In the murine cells, however, addition of LPS as 
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maturation factor does not convert the monocytes to inflammatory DCs but rather 
enhances their IL-10 secretion which inhibits allogenic T cell proliferation. Therefore, 
it has to be concluded that a species difference exists between murine and human 
monocytes in their differentiation response to CD137L reverse signaling. While 
human monocytes differentiate to inflammatory DCs murine monocytes do not. It is 
at present entirely unknown what the biological reason for this species difference may 
be.  
 
This species difference becomes also evident in the effects of CD137L reverse 
signaling on immature classical DCs generated by GM-CSF + IL-4. Exposure of 
human immature, classical DCs to CD137 protein or CD137-expressing cells induces 
maturation as evidenced by a higher expression of costimulatory molecules and IL-
12p70, stronger migratory activity and a higher T cell stimulatory capacity (Kim, Li et 
al. 2002, Lippert, Zachmann et al. 2008). In contrast, CD137L reverse signaling does 
not induce costimulatory molecule and IL-12p70 expression in murine immature DCs 
(Tang, Jiang et al. 2011). Most importantly, the CD137-treated murine DC does not 






4.1.2 What cell types are the CD137-treated monocytes? 
If CD137L reverse signaling cannot induce DC differentiation from 
monocytes, then what identity have the cells adopted?  
During an inflammatory state after monocytes exit the circulation they may 
become either macrophages or DCs based depending on the environmental cues 
(Geissmann, Manz et al. 2010). Therefore, it is quite likely that the CD137-treated 
monocytes differentiate to macrophages. Indeed, the enhanced phagocytic activity and 
the absence of allogeneic T cell stimulation strongly suggest that the CD137-treated 
monocytes have characteristics of macrophages. By comparing the CD137-treated 
monocytes to BMM generated by M-CSF, a highly similar cytokine profile is found 
between the two cells types, most notably the low IL-12p70/IL10 ratio. The induction 
of IL-10 production is further augmented by the addition of LPS. 
 
 The data corresponds well to previous studies by Shin in 2007 (Shin, Lee et 
al. 2007).  It was shown that immobilization of CD137 protein induced IL-10 
production from peritoneal macrophage. When mice received LPS injection, the 
influx of cells to peritoneal cavity is enhanced in CD137-/- mice because of impaired 
IL-10 production. Together with Shin’s data, interaction of CD137 and CD137L is 
crucial for IL-10 production in differentiated macrophage, particularly when 
synergized with LPS.  
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Crosslinking of CD137L on the murine monocytes also releases large 
amounts of MCP-1 which is a key chemokine for monocytes trafficking during 
infection (Huffnagle, Strieter et al. 1995, McCord, Burgess et al. 2005, Deshmane, 
Kremlev et al. 2009). The high level of MCP-1 suggests an activated state of the 
CD137-treated monocytes and may promote recruitment of phagocytes in vivo for 
pathogen clearance.   
 
4.1.3 Is the macrophage differentiation signal truly through CD137L? 
          When it is found that CD137L reverse signaling induces macrophage 
differentiation, a question arises whether the effect observed is truly the result of 
CD137L reverse signaling or due to binding of CD137 to other surface proteins such 
as other members of TNF receptor family that may share certain degrees of structural 
homology. Although it has been demonstrated by in vitro competitive assays that, 
unlike some of the TNF receptor super family members that are able to bind to 
multiple ligands, CD137 and CD137L are the sole receptor/ligand partner found so far 
(Bossen, Ingold et al. 2006), the possibility that CD137 may have hitherto 
unrecognized ligand outside the TNF family cannot be completely excluded. 
 
        Moreover monocytes can spontaneously differentiate to macrophages when in 
contact with ECM in vivo as well as when seeded on tissue culture dishes in vitro 
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(Jacob, Shastry et al. 2002, Sudhakaran, Radhika et al. 2007). Is it possible that the 
observed results are merely a combination of random binding of CD137 to surface 
protein and Fc fragment binding to Fc receptor on monocytes? 
 
        By using two other members of the TNF receptor super family, OX40 and 
TNFRI, the above possibilities are excluded because each of the individual receptor, 
CD137, OX40 and TNFR1 induce very unique morphological changes and cytokine 
profiles, suggesting that each receptor mediates the signal through its own ligand. 
Although it is not as effective in inducing cytokine production as TNFRI, CD137L 
reverse signaling is particularly effective in inducing attachment, survival and 
morphological changes compared to the two other members. Most importantly, all 
three recombinant proteins differ significantly from the Fc protein, clearly indicating 
that the observed attachment, morphological change and cytokine production are not 
merely mediated by random binding to another surface protein or attachment to the 







4.1.4 Underlying mechanism of species differences? 
The striking species differences in response to CD137L reverse signaling 
between murine and human monocytes begs the question what the underlying 
mechanism can be. This species difference may have its molecular basis in the low 
conservation of the human and murine CD137 ligand. While the amino acid sequence 
identity between other human and murine members of the TNF family ranges between 
70 and 80%, it is only 36% for CD137L. Therefore, it seems plausible that different 
signaling pathways and accordingly different biological effects are initiated by human 
and murine CD137L reverse signaling in the monocytes. Nevertheless, this species 
difference is unexpected since CD137L reverse signaling has the same effect on 
human and murine hematopoietic progenitor cells and induces macrophage 
differentiation in both species (Jiang 2008, Jiang, Yue et al. 2008). One possible 
explanation is that as the human and murine progenitor cells gradually lose plasticity 
of lineage potential, they develop distinct intrinsic changes, for example, a different 
epigenetic regulation and surface marker profile which leads to a different response to 
CD137L reverse signaling. Screening of gene regulation and surface marker profiles 






4.1.5 Other Concerns on species differences in CD137/CD137L biology 
It was not the first time that species differences between man and mouse 
were described for the CD137/CD137L system. While CD137 signaling delivers 
potent costimulatory signals to both human and murine T cells it affects NK cells 
differently in the two species. Crosslinking of CD137 by CD137L expressed on AML 
cell lines enhances the activity of murine NK cells while it inhibits the cytotoxicity 
and IFN-gamma release of human NK cells (Baessler, Charton et al. 2010). 
Combining the evidence from the above studies, one can foresee that the species 
differences between human and murine CD137/CD137L bidirectional signaling 
systems can significantly impact the interpretation of experimental data and 
eventually clinical trials. Agonistic CD137 antibodies have been viewed as a potent 
therapeutic tool because administration of the antibodies can reject established 
melanoma in mice (Melero, Shuford et al. 1997). However, it is possible that a large 
proportion of the therapeutic effect comes from the activating effect on murine NK 
cells (Baessler, Charton et al. 2010). Due to the inhibitory effect of CD137 on human 
NK cells, clinicians may face disappointing outcomes when administering the 
antibodies to human patients. On the other hand, while CD137L fails to generate DCs 
from murine monocytes, its ability to induce inflammatory DC from human 
monocytes should not be neglected, and it is possible to test the tumoricidal effect of 




Figure 4.1 Species difference between human and murine cells in response to 
CD137L stimulation in hematopoietic cells at different stages. Left panel: 
Differentiation pathway of human cells in in response to stimulation by CD137 
protein. Right panel: Differentiation pathway of murine cells in in response to 









4.2 The role of CD137L reverse signaling in myelopoiesis during infection  
Although CD137L reverse signaling shows a considerable species difference 
in the human and murine cells, the response of early progenitor cells is similar and 
CD137L remains a potent myeloid growth factor. It is particularly important to 
understand the effect of CD137L at the progenitor cells level because it is the one of 
the major compartments affected during many disease states. For instance, the origin 
of AML is caused by a differentiation arrest at the progenitor stage and malignant 
cells retain the proliferative property without further differentiation which usually 
leads to reduced mitotic potential (Catenacci and Schiller 2005, Licciulli, Cambiaghi 
et al. 2010, Alberich-Jorda, Wouters et al. 2012, Sexauer, Perl et al. 2012).  
 
Moreover during emergency myelopoiesis it is the progenitor compartment 
that responds to the proinflammatory stimulus and produces more cells to replace the 
loss in the periphery (Scumpia, Kelly-Scumpia et al. 2010, MacNamara, Oduro et al. 
2011). Hence, understanding the influence of CD137L during infection helps to 
elucidate the underlying mechanism of defective innate immunity such as neutropenia 





4.2.1 What is the source of CD137 during infection?  
Due to its inducible property, the level of CD137 at steady state is extremely 
low. If CD137L is to induce signaling into progenitor cells, the level of CD137 has to 
increase in the first place. Indeed during infection by various pathogens, including 
virus and extra- and intracellular bacteria, a significant increase of CD137+ cells is 
observed in the bone marrow compared to naïve mice by IHC. Further analysis by 
flow cytometry identified the cells as mainly T cells, with more than 60% of the cells 
expressing CD3. It is surprising, though, that the majority of the CD137+ T cells are 
actually CD4+ instead of CD8+ T cells because CD137 has been known to 
preferentially propagate CD8+ T cell population over CD4+
 
 T cells and promote Th1 
response during virus and mycobacterium infection (Shuford, Klussman et al. 1997, 
Lee, Park et al. 2002).  
In the context of myelopoiesis, however, the preference of CD4+ T cells over 
CD8+ T cells can be explained by their distinct roles in hematopoiesis. It has been 
reported that it was CD4+ T cells but not CD8+
Monteiro, Benjamin et al. 2005
 T cells that are essential to maintain 
normal myelopoiesis in bone marrow because reconstitution of the latter ones cannot 
rescue the defect myelopoiesis in athymic mice ( ). 
Even in the spleen, the major secondary lymphoid organ where extramedullary 
myelopoiesis occurs, CD4+ effector T cells were found to be responsible for myeloid 
cell development (Broxmeyer, Sehra et al. 2007, Lee, Wang et al. 2009). Moreover, it 
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was reported that CD4+ T cells instead of CD8+ T cells are the major sources of IFN-
gamma which is essential for HSCs activation and proliferation in the bone marrow 
during intracellular bacterial infection. Therefore, even though CD137 may 
preferentially activate CD8 T cell in the periphery, during infection, it is the CD4+
 
 T 
cells that have a higher expression of CD137 in the bone marrow to facilitate 
myelopoiesis.  
Can the CD137+ cells be myeloid cells such as DC that constitutively express 
CD137? Indeed CD137 has been shown to be expressed on both myeloid DC and 
activated bone marrow macrophages, and both cell types can reside in the bone 
marrow (Futagawa, Akiba et al. 2002, Saito, Ohara et al. 2004, Choi, Kim et al. 2009). 
Analysis of the myeloid marker CD11b on the CD137+ cells show that indeed about 
30% of the CD3-CD137+ cells are myeloid cells. However, whether the CD137+ 
myeloid cells contribute to the myelopoiesis during infection remains largely 
unknown. Based on the fact that the majority of the CD137+ cells that increase during 
infections are T cells, it is suggested that T cells are the major contributors of CD137 
to the bone marrow compartment. One may wonder what the rest of the CD3-CD137+ 
cells are. Under the microscope, aside from the few lamellipodia forming, myeloid-
like cells, the majority of the CD3-CD137+ cells appear round and are probably of 
lymphoid origin. One speculation is that the cells are NK cells. Their identities require 
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further investigation and how much they may contribute to the CD137-mediated 
myelopoiesis remains a topic for future investigation. 
 
4.2.2 Where do the CD137+
The next question is the origin of CD137
 T cells come from? 
+
 
 T cells. T cells are uncommon in 
bone marrow and usually comprise of only 1 to 3% of total cells during the steady 
state (Slifka, Whitmire et al. 1997, Herndler-Brandstetter, Landgraf et al. 2012). Then 
where do all the activated T cells expressing CD137 come from during infection? 
The first explanation is that activated T cells traffic from the periphery to the 
bone marrow, functioning as messenger to deliver the stimulating signal for 
myelopoiesis. This hypothesis is difficult to test directly because there is no means to 
label activated T cells in the periphery in order to distinguish them from the bone 
marrow residing T cells. Instead the hypothesis is tested indirectly by injecting CFSE 
labeled activated T cells to naïve mice i.v., mimicking a situation where T cells 
become activated in the periphery and traffick to other lymphoid tissue. The pattern of 
migration suggests that the activated T cells are able to migrate to bone marrow. 
Although the experimental set up does not completely recapitulate the in vivo 
situation, it was shown by other groups that during LCMV infection, T cells enter 
bone marrow and enhance myelopoiesis to combat the infection (de Bruin 2012). 
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Therefore, it is possible that during infection T cells become primed and activated in 
periphery such as lymph nodes and that some of these activated T cells migrate to the 
bone marrow. 
 
It should be noted, however, that the expression of CD137 does not convey 
an advantage on T cell migration as no increase in the expression of homing markers 
was observed between WT and CD137-/- activated T cells. One of the markers, 
CD62L, which is known to mediate the adhesion of leukocytes on blood vessels, was 
even slightly upregulated on CD137-/- T cells. The similar level of homing markers 
results in similar numbers of WT and CD137-/- T cells migrating to the bone marrow. 
In the spleen, CD137-/- T cells have surprisingly higher rates of migration than WT T 
cells, probably due to the higher CD62L expression that helps the extravasation of T 
cells in the vessel-rich spleen. How much the migratory efficacy contributes to the 
eventual output of myeloid cells is unclear. However, the number of cells may play a 
minor role because even with a higher influx of cells, CD137-/- 
 
T cells cannot 
crosslink CD137L in progenitor cells and mediate myelopoiesis.  
A second explanation is that resident T cells in the bone marrow become 
activated by dissemination of pathogen or cytokine to the bone marrow and enhance 
expression of CD137. The likelihood for this is low because in all the infection 
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models that have been tested, none of the pathogens is known to disseminate to the 
bone marrow. Induction of CD137 on T cells also requires ligation of TCR (Schwarz, 
Tuckwell et al. 1993, Schwarz, Valbracht et al. 1995). Therefore, even if the 
expression of CD137 on T cells is through systemic increase in proinflammatory 
cytokines, it cannot directly act on T cells. However, it cannot be excluded that an 
inflammation-induced cytokine storm causes a systemic reaction and activates 
myeloid cells in the bone marrow which in turn induce CD137 expression on T cells.  
 
4.2.3 What is the cell type responding to activated T cells during infection? 
           Bone marrow is composed of a mixture of cell populations including 
progenitor cells, B cells, monocytes, granulocytes and macrophages. Among all the 
cell populations, progenitor cells and monocytes are most likely the responding 
population to CD137+ T cells because both cell types have been shown previously to 
proliferate in vitro in response to recombinant CD137 protein (Jiang 2008, Jiang, Yue 
et al. 2008, Tang, Jiang et al. 2011). When cocultures of activated T cells were 
performed with either Lin- progenitor cells or total bone marrow cells, it was found 
both populations were able to proliferate, though at different rates. While WT T cells 
clearly promote more myeloid differentiation and proliferation of both cell 
populations compared to CD137-/- T cells, total bone marrow cells have a higher 
proliferation rate and higher myeloid differentiation than Lin- progenitor cells. Does 
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that mean progenitor cells have a weaker response to CD137 stimulation in 
myelopoiesis than total bone marrow cells? 
 
The data appear unexpected at first glance, but it is probably due to the 
mixed population present in total bone marrow cells. The majority of the cells that 
respond to CD137 treatment are monocytes, with the rest consisting of a small 
number of progenitor cells. Granulocytes and B cells probably undergo apoptosis due 
to insufficient growth support. While monocytes can only commit to the fate of 
macrophages or DCs, Lin- progenitor cells have a much wider choice. The 
differentiating efficacy of CD137 is not 100%, and part of the Lin- 
 
progenitor 
population may escape the influence of CD137 and commit to other lineages. 
Therefore, in the case of total bone marrow, the majority of the responding cells can 
only become or maintain myeloid proliferation or differentiation. On the other hand, 
when the responding cells only consist of progenitor cells, part of the population 
retains the ability to differentiate to lineages other than myeloid cells, resulting in a 





4.2.4 Why is extramedullary myelopoiesis not affected by CD137L reverse 
signaling? 
When assessing the level of myelopoiesis in the bone marrow of infected 
mice, a higher number of BrdU+ myeloid cells were found in the bone marrow, 
suggesting that the observed enhanced myelopoiesis was not due to mobilization of 
granulocytes and monocytes from the bone marrow compartment to the periphery. 
Rather it was due to local proliferation as the cells actively incorporate BrdU, a 
nucleotide analog. It is interesting that an increase of proliferation was only observed 
in the bone marrow but not in the spleen. Does that mean that CD137L reverse 
signaling has no effect on extramedullar myelopoieisis during infection? The 
explanation may lie in the cell composition in the spleen. Unlike in the bone marrow 
where the majorities of the cells are immature and retain the potential for proliferation 
and differentiation, the spleen consists mainly of terminally differentiated myeloid 
cells with limiting ability to proliferate. Although HSCs reside in the spleen during 
steady state, and are reported to migrate from bone marrow to spleen during infection 
or tumor growth, their frequency in spleen is much lower than that in the bone 
marrow, and the splenic HSCs have a lower proliferation rate and longer cell cycle 
(Morita, Iseki et al. 2011). Therefore, it may not be surprising that the number of 
proliferating myeloid cells is relatively lower than that of bone marrow. The low 




In addition, previously it was shown that CD137-/- T cells can mobilize to the 
spleen more efficiently than WT T cells. In spite of their possible higher migratory 
property WT and CD137-/- 
 
mice do not differ in extremedullar myelopoiesis during 
infection, again suggesting that the pivotal factor of myelopoiesis lies in the 
expression of CD137 instead in the number of T cells that have trafficked to the 
lymphoid organs.  
4.2.5 Is CD137L reverse signaling the sole mechanism of the observed 
myelopoiesis 
           Besides surface-bound CD137, activated T cells secrete numerous cytokines 
including GM-CSF, G-CSF, IL-3 and M-CSF. Many of these cytokines can promote 
myelopoiesis. Therefore, one may ask the question whether CD137L reverse signaling 
is the only mechanism responsible of the myelopoiesis, both in vitro and in vivo? The 
level of myeloid growth factors in the coculture of Lin- progenitor cells and activated 
CD4+ T cells has been tested for GM-CSF, G-CSF and M-CSF. Surprisingly, the 
levels of both GM-CSF and G-CSF were higher in cocultures of CD137-/- than WT T 
cells with Lin- progenitor cells, even though the Lin- progenitor cells in this coculture 
had reduced proliferation and myeloid differentiation. If GM-CSF and G-CSF 
contribute to the myelopoiesis, one would have expected that Lin- progenitor cells in 
the coculture with CD137-/- T cells have a comparable or even a higher degree of 
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myeloid differentiation. Instead, the data rather proved that the influence of CD137L 
reverse signaling on Lin-progenitor cells surpasses that of GM-CSF and G-CSF.   
 
          Why CD137-/- T cells produce more GM-CSF and G-CSF remains unclear. 
ELISA data of supernatants from activated WT and CD137-/- T cells showed that 
when activated by anti-CD3 and anti-CD28 antibodies T cells from the two strains 
produce similar levels of GM-CSF. However when cocultured with progenitor cells 
CD137-/- T cells have a higher production, suggesting an involvement of CD137L. 
The data actually fit to previous findings that splenocytes but not purified T cells from 
CD137-/- mice hyperproliferate when activated (Kwon 2002). The reason that total 
splenocytes instead of purified T cells indicates that CD137L on other cell types must 
crosslink the CD137 on T cells to prevent hyperproliferation. In the coculture system 
the Lin- progenitor cells and monocytes express CD137L and therefore, crosslink 
CD137 on WT T cells to prevent hyperproliferation while in the activated CD137-/- 
 
T 
cells such a braking system is absent. The higher number of T cells may result in a 
larger amount of GM-CSF and G-CSF in the supernatants.  
The in vivo situation is far more complicated than the in vitro system as other 
immune and non-immune cell types are involved in the process as well. CD137 has 
been shown to be expressed on endothelial cells stimulated by TNF-alpha, LPS and 
144 
 
IL-1 beta. Crosslinking of CD137 causes production of the chemokine CCL21, 
leading to leukocytes infiltration and cytokine storm including IFN-gamma and MCP-
1 (Jeon, Choi et al. 2010, Teijeira, Palazon et al. 2012). As previously discussed, 
many of the proinflammatory cytokines such as IFN-gamma, IFN-beta and IL-6 
favor myelopoiesis. Therefore, the possibilities that these cytokines play certain roles 
in the CD137L-mediated myelopoiesis cannot be completely excluded.  
 
Last but not the least CD137L may exert its influence on myeloid 
differentiation by upregulating receptors for cytokines, for instance, GM-CSFR, M-
CSFR and FLT-3. Currently no reports have touched on this subject although 
CD137L reverse signaling on human monocytes has been shown to induce M-CSF 
which acts in an autocrine manner to promote monocytes proliferation and survival 
(Langstein, Michel et al. 1999, Langstein and Schwarz 1999).  
 
4.2.6 Is CD137L reverse signaling absolutely dependent on CD137 crosslinking? 
Although studies have shown that so far CD137 is the only recognized 
receptor for CD137L (Bossen, Ingold et al. 2006), evidence has emerged that on 
occasions CD137L can signal without the presence of CD137. A study employing 
yeast-two-hybrid screen found that CD137L can associate with TLR-4 and induce 
signal on macrophages (Kang, Kim et al. 2007). The formation of this signaling 
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complex is completely independent of CD137. Moreover, the CD137L-TLR-4 
complex is required for a sustained TNF-alpha production in macrophages. Even 
though in the absence of this complex, TNF-alpha can be produced in large quantities, 
the production returns quickly to base level without CD137L. Another study by Moh 
showed that in human THP-1 cell line CD137L binds to TNFRI (Moh, Lorenzini et al. 
2013). Different from the previous case, association of CD137L and TNFRI requires 
crosslinking of CD137.   
 
Whether there are other surface proteins that CD137L may bind to is still to 
be elucidated. However, based on current knowledge, it can be speculated that the 
association of CD137L and other surface proteins may have a significant impact on 
the cell population it is expressed on. In the case of myelopoiesis, TLR-4 has been 
reported to be expressed on HSCs. It is possible that TLR-4 expressed on HSCs can 
associate with CD137L and hence mediate reverse signaling. Based on the in vivo 
model of acute peritonitis, the data suggest that in the case of infection-induced 
myelopoiesis, CD137-CD137L interaction is necessary for the action because in 
CD137-/- mice where the receptor is missing, mice have fewer proliferating cells than 
their WT counterparts. Besides, even though CD137L has been proven to associate 
with TLR-4 and the interaction of the two molecules is required for a sustained TNF-
alpha production, the signaling pathway my differ from the one initiated by CD137 
crosslinking. It cannot be excluded that the two signaling pathways overlap in certain 
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functions. The association of TLR-4 and CD137L may even augment the response of 
HSC to CD137 stimulation. A double-knockout mouse strain without both TLR-4 and 
CD137L can answer the question. 
 
4.2.7 What is the significance of the biphasic role of CD137L reverse signaling in 
myelopoiesis? 
    The data on CD137L reverse signaling during infection indicate a biphasic 
role of the molecule in myelopoiesis: inhibitory during steady state but proliferative 
during inflammation. Such a phenomenon is not limited to CD137L. It was also 
reported that IFN-gamma limits myeloid lineage colony formation when added in 
vitro but is essential for monocytes development during LCMV infection 
(MacNamara, Oduro et al. 2011, de Bruin 2012). Similarly, IFN-beta also inhibits 
myelopoiesis in vitro but promotes myeloid cells development in vivo (Deonarain, 
Verma et al. 2003, Wilkison, Gauss et al. 2012). The complete opposite effects of 
these inflammatory molecules including CD137L are possibly regulatory mechanisms 
of the immune system: the low constitutive level of the molecule present in the 
primary hematopoietic compartment during steady state is to prevent excess myeloid 
cells output that may produce undesirable inflammation and tissue damage. It is also 
to prevent a compromising lymphopoieisis when the hematopoieisis skews to 
myelopoiesis. The switch from inhibition to promotion occurs when large amounts of 
these inflammatory cytokines are introduced by pathogen invasion. Under such 
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emergency situations the proinflammatory molecules function as an alarm signal by 
increasing concentrations or expression levels in the bone marrow compartment and 
drive the hematopoiesis into an emgergency myelopoiesis. 
 
It should be noted that the CD137L reverse signaling mediated myelopoiesis 
may not be limited to a particular infection model as similar increases of CD137+ T 
cells are observed in the bone marrow of mice infected with E. coli or receiving LPS 
injection. While E. coli is a natural pathogen, LPS is only a bacterial cell wall 
component that induces systemic inflammation. It is more likely that the enhanced 
expression of CD137 is a general response of inflammation regardless of the nature of 
the cause. It is even possible that CD137L reverse signaling may contribute to the 
production of inflammatory myeloid cells in autoimmune diseases such as EAE and 
rheumatoid arthritis.   
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Figure 4.2 Model CD137L reverse signaling induces myelopoiesis during 
infection. Infection by pathogen induces T cell activation and CD137 expression. The 
activated T cells migrate to the bone marrow and crosslink CD137L on HSCs to 
promote myelopoiesis. The increased numbers of myeloid cells exit the bone marrow 











4.3 Role of CD137L reverse signaling in age-related myelopoiesis 
The previous section demonstrates that the CD137/CD137L system plays a 
dichotomic role, inhibiting myelopoiesis during steady state conditions and inducing 
myelopoiesis during inflammatory conditions. It also identifies a novel mechanism of 
infection-induced myelopoiesis by demonstrating that the interaction of CD137 on 
activated CD4+
 
 T cells and CD137L on HSCs induces myelopoiesis during infections. 
Age-related disruption in hematopoiesis is a well-known phenomenon and 
has been linked to development of various types of disease including the increasing 
occurrence of infection and tumor incidents (Gruver, Hudson et al. 2007, Hakim and 
Gress 2007). Understanding the underlying mechanisms that skew hematopoiesis 
towards myelopoiesis will facilitate in implanting new therapeutic tools for 
intervening the process.  
 
The role of proinflammatory molecules in driving myelopoiesis has been 
extensively investigated in the last decade. Cytokines including IFN-γ and TNF-α 
have been reported to be essential for myeloid cell development (MacNamara, Oduro 
et al. 2011, de Bruin 2012, Oduro, Liu et al. 2012). It is considered a positive 
feedback mechanism to the hematopoietic system to increase numbers of myeloid 
cells which are the major forces in combating infection. In the context of aging, 
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however, these proinflammatory cytokines may be the promoting factors for bias 
towards myelopoiesis.  
 
Based on the role of CD137L reverse signaling on myelopoiesis during acute 
inflammation mediated by E. coli infection, this section discusses its effect on aging 
where mice experience low degree of chronic inflammation. 
 
4.3.1 Is CD137L a driving force of myelopoiesis during aging? 
The next question to address is the role of CD137L reverse signaling in 
myelopoiesis during aging. Previously it has been reported that CD137L reverse 
signaling enhances myelopoiesis during inflammation. Since aging is also an 
inflammatory process it is asked whether CD137L is essential for myelopoiesis during 
this process. The major newly differentiated myeloid populations derived from 
progenitor cells are mainly granulocytes and monocytes. The data showed that in the 
absence of CD137L or CD137, mice of 12-months of age do not experience a similar 
increase in the numbers of granulocytes and monocytes as WT mice, strongly 
suggesting that the myeloid skewing process in the CD137-/- and CD137L-/- mice is 
stalled. This phenomenon is similar to the published data where CD137L reverse 
signaling enhances myelopoiesis during inflammation (Tang, Jiang et al. 2013). Both 
CD137-/- and CD137L-/- mice showing reduced myelopoiesis in aged animals strongly 
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suggests that the age-related myelopoiesis depends on the interaction of CD137 and 
CD137L. 
 
4.3.2 What is the role of CD137+
Contrasting to the findings in the infection models where CD137
 T cells in age-related myelopoiesis? 
+ CD4+ T 
cells accumulate during the inflammation, no increased number of CD137+ CD4+ T 
cells in the 12-months WT mice was observed compared to their 3-months 
counterparts. This is probably due to the different degrees of inflammation the mice 
experience. During acute peritonitis mice develop symptoms of inflammation within 
48 hr while in the aging model mice have only low degree of chronic inflammation 
throughout 12 months. Therefore, possibly the low numbers of CD137+ CD4+ cells 
are sufficient to maintain the myelopoiesis while the fast expansion of CD137+ CD4+
 
 
T cells is only required during emergency myelopoiesis where a quick response is 
needed for pathogen clearance.  
It is interesting that a significant increase of CD137+ CD4+ T cells in 12-
months CD137L-/- mice is observed in spite of the lower myelopoiesis in the bone 
marrow. One potential explanation could be the reciprocal relationship between 
expression levels of CD137 and CD137L, where a decrease of CD137L expression 
leads to an increase in CD137 expression, and vice versa (Wang, Lin, Ho et al., 2013; 
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Wang et al., 2009). An alternative explanation may be due to an unclosed feedback 
loop. Since CD137+ CD4+ T cells function as stimulators of myelopoiesis, and since a 
positive feedback signal in the form of more myeloid cells does not occur in the 
absence of CD137L reverse signaling, the CD137+ CD4+
 
 T cells continue to home to 
the bone marrow. 
The phenotype of the CD137+ CD4+ T cells may differ from the ones 
observed during infection. While the CD137+ T cells whose numbers increase during 
infections are probably effector T cells primed in the periphery, the accumulated T 
cells in aged animals are possibly memory T cells that have encountered antigen in 
the periphery and homed to the bone marrow during the aging process. Previous 
studies on T cells in bone marrow of aged adults indicated that CD4+ and CD8+
 
 T 
cells in the bone marrow are mainly antibacterial and anti tumor memory T cells 
(Herndler-Brandstetter, Landgraf et al. 2011). This speculation needs to be validated 
by further experiments that examine the surface marker profile of the T cells in the 
bone marrow of mice with infection and of aged mice. 
A general increase of CD137-CD4+ T cells is observed in the bone marrow of 
aged animals in all three strains of mice. This accumulation is independent of the 
expression of CD137 or CD137L. It seems unlikely that this population plays a major 
role in the age-related myelopoiesis because all three strains of mice have similar 
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numbers of CD137-CD4+ T cells.  However, it cannot be excluded that inherent 
changes have been induced in the T cells across the strains. Despite their similar 
numbers, it is unknown whether the T cells from CD137-/- and CD137L-/- aged mice 
actually have reduced cytokine production or a different surface marker expression 
profile that may eventually affect their function in the age-related myelopoiesis. 
Previous findings have shown that in spite of their hyperproliferation, the cytokine 
production of CD137-/- T cells is clearly impaired when activated through TCR 
(Kwon 2002). Recently it was reported that during infection CD4+ T cells instead of 
CD8+ T cells are the major source of IFN-gamma which is required for HSCs 
activation and proliferation during intracellular bacterial infection. Therefore, it is 
possible that the CD4+ T cells in the bone marrow of the knock out strains are 
dysfunction in terms of cytokine production and have a smaller impact on 
myelopoiesis than WT CD4+ T cells. To better compare the functions of bone marrow 
residing T cells in myelopoiesis, it will be useful to sort out the CD4+ and CD8+ T 
cells from bone marrow of aged WT, CD137-/- and CD137L-/-
 
 mice and compare them 
to their young counterparts.  
4.3.3 Is CD137L necessary for transition from progenitor cells to mature cells? 
Because the myelopoiesis level of CD137L-/- mice is much lower than of WT in 
spite of the increased numbers of CD137+ and CD137- CD4+ T cells, it is suspected 
that the recipient of the signal, mainly the myeloid progenitor cells, may experience a 
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block while transiting from the progenitor stage to the more differentiated 
granulocytes and monocytes. Proinflammatory cytokines are known to shift the 
myeloid progenitor cells to downstream granulocytes and monocytes during 
inflammation (MacNamara, Oduro et al. 2011). It was found that indeed numbers of 
both KSL and myeloid progenitor cells were significantly increased by the aging 
process in CD137-/- and CD137L-/- mice but remained unchanged in the WT mice, 
indicating an accumulation of undifferentiated hematopoietic cells in the two knock-
out strains. The data of colony forming assays further confirmed that the two knock-
out strains, particularly the CD137L-/-
 
 mice, had higher numbers of myeloid colony 
forming units during aging. The data strongly suggest that the absence of CD137L 
reverse signaling causes a differentiation block in the progenitor cells, and hence 
arrests them at the less differentiated stage, leading to lower numbers of mature 
granulocytes and monocytes in the bone marrow.  
The direct link between activated CD4+ T cells and myeloid differentiation of 
progenitor cells is confirmed by coculture of activated WT CD4+ T cells with WT or 
CD137L-/- Lineage- progenitor cells where the lack of CD137L reverse signaling 
strongly diverts the progenitor cells away from the myeloid lineage as shown by a 
lower numbers of CD11b+, Ly6G+ and Ly6C+
 
 cells.  
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Notably other groups have reported that during steady stage CD137-/- and 
CD137L-/- progenitor cells have a higher myeloid differentiation potential and 
turnover rate in naïve young mice (Kwon 2002, Lee, Park et al. 2008). These data are 
not necessarily contradictory to the observation in the aging model. CD137L reverse 
signaling at steady stage may serve as a regulator of myelopoiesis to prevent 
overproduction of myeloid cells. Although the absence of CD137L reverse signaling 
may subject the myeloid progenitor cells to a higher turnover rate , under 
inflammation where CD137L is required for terminal differentiation to granulocytes 
and monocytes, the progenitor cells cannot exit and therefore, continue to accumulate 
in the bone marrow. Such seemingly conflicting role of CD137L was also reported in 
other studies where activation of CD137L on B cells led to proliferation in vitro 
(Pollok, Kim et al. 1994, Pauly, Broll et al. 2002) while in vivo CD137L regulates 
hyperproliferation of germinal centre B cells, evidenced by the fact that aged 
CD137L-/-
 
 mice tend to develop germinal B cell lymphoma (Middendorp, Xiao et al. 
2009). 
4.3.4 Implication of CD137L-mediated myelopoiesis during aging 
It is particular important to understand the mechanism underlying biased 
myelopoiesis during aging because this is one of the driving forces that cause an 
imbalance in the hematopoietic system. As previously mentioned, researchers have 
been experimenting to rejuvenate the lymphopoiesis in aged mice by depleting 
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peripheral B cells (Keren, Naor et al. 2011). With the understanding of the role of 
CD137L reverse signaling in aged-related myelopoiesis, there may be additional 
approaches to reprogram the aging hematopoietic system. Neutralizing antibodies 
targeting CD137L on HSCs can be developed to block the interaction between 
progenitor cells and T cells. In a future study, it would be interesting to see whether 
aged CD137-/- and CD137L-/- 
 
mice have enhanced vaccine efficacy or lower tumor 
development than WT mice. On the other hand, due to their higher number of innate 
myeloid cells, aged WT mice may have an advantage over the two knock out strains 
in acute bacterial infections as they can clear the pathogen in a faster manner.  
Is the myelopoiesis driving effect of CD137L reverse signaling absolutely 
deleterious? Not necessarily. Without proceeding to terminal differentiation of 
granulocytes and monocytes the progenitor cells become arrested at the immature 
stage and hence prone to the development of malignant leukemia such as AML. The 
development of leukemic cells usually starts with genetic mutations in a few clones 
which escape immune surveillance and continue to expand. In the case of 
CD137/CD137L system, besides the inability to promote myelopoiesis, CD137-/- and 
CD137L-/- mice may also be inferior to the WT counterparts in eliminating leukemic 
clones. In the future it would be interesting to know whether aged CD137-/- and 
CD137L-/- mice have more genetic mutations or DNA damage than aged WT 
progenitor cells.  
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Figure 4.3.2 Model of CD137L-mediated myelopoiesis in aging animals. 
CD137+CD4+ T cells in bone marrow of aged animals continuously promote 
differentiation of hematopoietic progenitor cells to mature myeloid cells. In the 
absence of CD137, progenitor cells accumulate at the undifferentiated stage and fail 
to progress to the downstream myeloid cells. When CD137L is absent from the 
progenitor cells, CD137+CD4+
 
 T cells keep homing to the bone marrow due to the 
missing increase of myeloid cells in the periphery. The progenitor cells are arrested in 












Chapter 5 Conclusion 
       In this project, the role of CD137L reverse signaling in myeloid cells has been 
investigated in the context of acute and chronic inflammation. 
 
 Firstly this project addresses the issue of the species difference of CD137L 
reverse signaling between human and murine monocytes. Although the inability of 
CD137L reverse signaling to induce murine DC differentiation limits the usage of 
murine model for testing the tumoricidal effect of CD137L-DC in vivo, it brings up 
the awareness of potential implication of exploiting CD137/CD137L system in 
clinical usage. 
 
Furthermore the findings in both acute and chronic inflammation in the 
context of infection and aging respectively show that CD137L reverse signaling is a 
driving force for myelopoiesis, mainly mediated by CD137+ CD4+
 
 T cells. In the 
future manipulation of the CD137L reverse signaling pathway may provide insight of 
therapeutic tools for dysregulated hematopoiesis. The data also resolve long lasting 
conflict on the role of CD137L reverse signaling in myelopoiesis during steady and 
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Appendix I Buffer and solutions 
PBS (Working concentration, 1x) 
8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.24g KH2PO4 in 1L H2O, ph7.4 
 
FACS buffer 
0.5% FBS, 0.02%NaN3 in PBS, Ph7.4 
 
MACS buffer 
0.5% FBS, 2mM EDTA in PBS, Ph7.4 
 
RBC lysis buffer 
0.15M NH4Cl, 10mM KHCO3, 0.1Mm Na2EDTA in H2O, Ph 7.4 
 
ELISA wash buffer (PBST) 
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